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Introduction
1. INTRODUCTION
1.1 ORAL DRUG DELIVERY [1]:
Most conventional oral drug products, such as tablets and capsules, are formulated to
release  the  active  drug  immediately  after  oral  administration,  to  obtain  rapid  and
complete  systemic  drug  absorption.  Such  immediate  release  products  result  in
relatively  rapid  drug  absorption  and  onset  of  accompanying  pharmacodynamic
effects.  However,  after  absorption  of  the  dosage  form  is  complete,  plasma  drug
concentration decline according to drug’s pharmacokinetic profile. Eventually, plasma
drug concentration fall below the minimum effective plasma concentration (MEC),
resulting in loss of therapeutic activity. Before this point is reached, another dose is
usually  given  if  a  sustained  therapeutic  effect  is  desired.  An  alternative  to
administering another dose is to use a dosage form that will provide sustained drug
release, and therefore maintain plasma drug concentrations, beyond what is typically
seen using immediate release dosage forms.
1.2 MODIFIED DRUG DELIVERY:
The term modified release drug product is used to describe products that alter the
timing and/or the rate of release of the drug substance. A modified-release dosage
form is defined as one for which the drug-release characteristics of time course and/or
location are chosen to accomplish therapeutic or convenience objectives not offered
by conventional dosage forms such as solutions, ointments, or promptly dissolving
dosage  forms  as  presently  recognized.  Several  types  of  modified-release  drug
products are recognized.
 Modified  release  delivery  systems  may  be  divided  conveniently  in  to  four
categories:
A. Delayed release
B. Controlled release
i. Sustained release
ii. Extended release
C. Site specific targeting
D. Receptor targeting
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 A. Delayed Release:
        These systems are those that use repetitive, intermittent dosing of a drug from
one  or  more  immediate  release  units  incorporated  in  to  a  single  dosage  form.
Examples  of  delayed  release  systems  included  repeat  action  tablets,  capsules  and
enteric-coated tablets where timed release is achieved by barrier coating.
B. Controlled release systems: 
        These systems include any drug delivery systems that achieves slow release of
drug over an extended period of time and also can provide some control, where this be
of a temporal or spatial nature, or both, drug release in the body, or in other words, the
system is successful at maintaining constant drug levels in the target tissue or cells.
i) Sustained release:
These  systems  include  any  drug  delivery  system  that  achieves  slow
release of drug over an extended period of time.
ii) Extended release:
Pharmaceutical dosage forms that release the drug slower than normal
manner and necessarily reduce the dosage frequency by two folds. 
C. Site specific targeting:
           These systems refer to targeting of a drug directly to a certain biological
location. In this case the target is adjacent to the effected organ or tissue.
D. Receptor targeting: 
           These systems refer to targeting of a drug directly to a certain biological
location. In this case the target is the particular receptor for a drug with in organ or
tissue.
 1.3 EXTENDED RELEASE DOSAGE FORMS [2]:
            Dosage forms which can reduce at least a two fold reduction in dosing
frequency as compared to the drug presented in a conventional form, such as solution
or a prompt releasing conventional solid dosage form are termed as extended release
dosage forms.
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           These products are formulated to make the contained medicament available
over an extended period of time after administration within its therapeutic range and
hence reduction in dosing frequency as compared to the conventional dosage forms. 
          Comparison of different types of modified release dosage formulations as per 
plasma concentration vs. time can be explained by the following figure. (1)
     
                                  Figure No.1: plasma concentration vs. time
         
ADVANTAGES AND DISADVANTAGES OF ORAL EXTENDED RELEASE
DOSAGE FORMS
             All sustained release dosage forms have a common goal of improving the 
drug therapy compared to that achieved by their non sustained counter parts.
Advantages
•  Avoid patient compliance problems
•  Employ less quantity drug.
•  Minimize or eliminate local side effects.
•  Minimize or eliminate systemic side effects.
•  Reduce dosing frequency and fluctuation of therapeutic plasma concentration
•  Obtain less potentiation or reduction in drug activity with chronic use.
•  Minimize drug accumulation with chronic dosing.
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Introduction
•  Improves efficiency in treatment
•  Cures or control conditions more promptly.
•  Improves control of condition i.e., reduces fluctuations in drug level.
•  Improves bioavailability of some drugs.
•  Makes use of special effects in sustained release aspirin for morning relief of 
arthritis by dosing before bedtime.
• Economy
Disadvantages
• Dose dumping, toxicity can occur if system fails.
• Reduced potential for accurate dose adjustments.
• Need for additional patient education.
• Does not permit the prompt termination of drug therapy.
• Cannot exercise any control once the dosage form is administered.
1.3.1 TYPES OF EXTENDED RELEASE PRODUCTS:
(a) Diffusion Controlled Products
In these a water-insoluble polymer which controls the flow of water and the
subsequent  release  of  dissolved  drug  from  the  dosage  form.  Both  diffusion  and
dissolution  processes  are  involved.  In  `reservoir'  devices,  a  core  of  drug  is
encapsulated with in a polymer coat, and in `matrix' systems, the drug is dispersed
throughout  the  matrix.  Cellulose  derivatives  are  commonly  used  in  the  reservoir
types,  while  the  matrix  material  may  be  plastics,  e.g.  methylacrylate-methyl
methacrylate, polyvinyl chloride, hydrophilic polymers such as cellulose derivatives
or fatty compounds including carnauba wax. Examples of this type of formulation
include Agon SR, Kapanol and Slow-K. [2,3]
(b) Dissolution Controlled Products
The rate of release of the drug (and there by availability for absorption) is
controlled by slowly erodible/ soluble polymers or by micro encapsulation of drugs
with  slowly  soluble  polymers.  Once  the  coating  is  dissolved,  the  drug  becomes
available for dissolution. By varying the thickness of the coat and its composition, the
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rate of drug release can be controlled. Some preparations contain a fraction of the
total  dose as an immediate-release component to provide an immediate dose soon
after administration.
              The pellet dosage forms of diffusion or dissolution controlled products can
be  encapsulated  or  prepared  as  a  tablet.  Encapsulated  pellet  products  have  an
advantage  that  the onset  of  absorption is  less sensitive to stomach emptying.  The
entrance of the pellets into the small intestine (where the majority of drug absorption
occurs) is usually more uniform than with non-disintegrating extended-release tablet
formulations. An example of this type of product is Fefol [4].
(c) Erosion Products
              The release of drug from these products is controlled by the erosion rate of a
carrier matrix. The rate of release is determined by the rate of erosion. An example of
this formulation is Sinemet CR. This product, some patients may experience a delayed
onset of action after the morning dose, compared to conventional levodopa tablets,
because of the delayed release of the drug.
(d) Osmotic pump systems
              The rate of release of drug from this drug delivery system is maintained by
the constant  inflow of  water  across  a  semi permeable  membrane into a  reservoir,
which contains an osmotic agent. The drug is either mixed with the agent or is located
in a reservoir. The dosage form contains a small hole from which dissolved drug is
pumped at a rate determined by the rate of entrance of water due to osmotic pressure.
The rate of release is constant and can be controlled within limits yielding relatively
constant  blood  concentrations.  The  advantage  of  this  type  of  product  is  that  the
constant release is unaltered by the environment of the gastrointestinal tract and relies
simply on the  passage  of  water  into  the dosage  form.  The rate  of  release  can be
modified by altering the osmotic agent and the size of the hole. An example of this
type of product is ALZET. [3,4]
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Ion exchange systems
             Some drugs can be bound to ion exchange resins and, when ingested, the
release  of  drug is  determined by the ionic environment within the gastrointestinal
tract.  Examples  of  this  type  of  product  are  Duromine  containing  the  basic  drug
phentermine complexed onto an anionic resin [4].
1.3.2 FACTORS TO BE CONSIDER IN DESIGN OF EXTENDED RELEASE
PRODUCTS:
             To successfully design extended release drug delivery system for a given
drug, information about drug like,
• The properties of the drug, its behavior in biological  systems, its biological
half life is essential.
• The  Absorption,  Distribution,  Metabolism  and  Elimination  (ADME)
characteristics  of  the  drug  will  enable  the  development  of  mathematical
models to adequately describe the transit of the drug in the system.
• The relationship between the absorption and the blood concentration.
• The desired profile of therapeutic  action with these kinds of segments  like
rapid rise, constant tissue level and rapid concentration.
• Information related to the tendency of the drug to get accumulated or bound to
plasma proteins and any body tissue.
• The route of administration, the dose and the ultimate pharmacological action.
• Various physical and chemical properties of the drug.
1.3.3 MECHANISM OF EXTENDED RELEASE:
The rate of release of a drug dispersed as a solid in an inert matrix has been
described by Higuchi. In this model it is assumed that the solid drug is dissolved from
the surface layer of device first and this layer becomes exhausted of the drug; the next
layer begins to get depleted by dissolution and diffusion through the matrix, to the
external solution. In this fashion interface between the regions containing dissolved
drug and that containing the dispersed drug moves to the interior as a front[2,3].
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The assumptions which are made in deriving the mathematical models are as follows:
• A pseudo steady state is maintained during the release.
• The  total  amount  of  drug  present  per  unit  volume  in  the  matrix,  C0 is
substantially greater than the saturation solubility of drug per unit volume in
the matrix Cs
• The release media is the perfect sink at all times.
• Drug  particles  are  much  smaller  in  diameter  than  the  average  distance  of
diffusion.
• The diffusion coefficient remains constant.
• No interaction occurs between drug and the matrix.
          Schematic representation of the physical model used for a planar slab matrix
diffusion device based on the above assumptions, the change in the amount of the
drug released per unit area, dM with a change in the depleted zone thickness dh, is
                       dM = Codh – (Cs/2) dh ------------- (a)
Where, Co and Cs is the drug present per unit volume and saturation solubility 
respectively.
                      dM = (Dm. Cs / h) dt ---------------- (b)
Where, Dm is the diffusion coefficient of the matrix.
        If the equation a and b are equated, and solved for h , and that value of ‘h’ was
substituted  back  in  to  the  integrated  form  of  equation(b)  an  equation  for  M  is
obtained.
                    M = [Cs Dm (2Co - Cs) t] 1/2 ------------(c)
Similarly, a Drug release from a porous granular matrix is described by,
                    M = [Cα Ds (ε / T) (2Co – ε Cα) t]1/2 --------- (d)
Where, ε is porosity of matrix,
T is tortuosity,
Cα is the solubility of drug in the release medium,
Ds is diffusion co-efficient of drug in the release medium.
For the purposes of the data treatment, equation (b) and (c) are conveniently reduced 
to
                  M = Kt1/2
Where K is a constant, so that a plot an amount of drug released versus square root of
time should be linear if the release of drug is diffusion controlled.
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1.4 MULTI PARTICULATE DRUG DELIVERY SYSTEM:
Multi-particulate  drug  delivery  systems  are  mainly  oral  dosage  forms
consisting  of  a  multiplicity  of  small  discrete  units,  each  exhibiting  some  desired
characteristics. In these systems, the dosage of the drug substances is divided on a
plurality  of  subunit,  typically  consisting  of  thousands  of  spherical  particles  with
diameter  of 0.05-2.00 mm. Thus multiparticulate  dosage forms are pharmaceutical
formulations  in  which  the  active  substance  is  present  as  a  number  of  small
independent subunits. To deliver the recommended total dose, these subunits are filled
into a sachet and encapsulated or compressed into a tablet [5,6].
Multiparticulates are discrete particles that make up a multiple unit system.
They provide many advantages over single-unit systems because of their small size.
Multi-particulates are less dependent on gastric emptying, resulting in less inter and
intra-subject variability in gastrointestinal transit time. They are also better distributed
and less likely to cause local irritation. Recently much emphasis is being laid on the
development of multiparticulate dosage forms in preference to single unit  systems
because of their potential benefits such as increased bioavailability, reduced risk of
systemic toxicity, reduced risk of local irritation and predictable gastric emptying [7,8]. 
There are many reasons for formulating a drug as a multiparticulate system for
example, to facilitate disintegration in the stomach, or to provide a convenient, fast
disintegrating  tablet  that  dissolves  in  water  before  swallowing  which  can  aid
compliance  in  older  patients  and  children.  Multiparticulate  systems  show  better
reproducible pharmacokinetic behavior than conventional (monolithic) formulations.
After disintegration which occurs within a few minutes often even within seconds, the
individual subunit particles pass rapidly through the GI tract. If these subunits have
diameters of less than 2 mm, they are able to leave the stomach continuously, even if
the pylorus is closed. These results in lower intra and inter individual variability in
plasma levels and bioavailability.
 
1.4.1 SOME APPROACHES TO MULTIPARTICULATE FORMULATION:
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The site-specific delivery of drugs to the colon has implications in a number of
therapeutic  areas,  which  include  topical  treatment  of  colonic  disorders  such  as
Crohn’s disease, ulcerative colitis, constipation, colorectal cancer, spastic colon and
irritable  bowel  syndrome.  Multiparticulates  approaches  tried  for  colonic  delivery
includes  formulations  in  the  form  of  pellets,  granules,  microparticles  and
nanoparticles. Because of their smaller particle size compared to single unit dosage
forms these systems are capable of passing through the GI tract easily leading to low
inter and intra subject variability. Moreover, multiparticulate systems are to be more
uniformly dispersed in the GI tract and also ensure more uniform drug absorption.
Multiparticulates  may be  prepared  by several  methods.  Different  methods require
different  processing  conditions  and  produce  multiparticulates  of  distinct  qualities.
Some of these methods may be broadly classified as: 
• Pelletization
• Granulation 
• Spray drying 
• Spray congealing
 Drug  particles  may  be  entrapped  within  the  multiparticulates  or  layered
around them. Subsequently, these multiparticulates may be modified in many ways to
achieve the desired drug release profile. One approach to the modification of drug
release  profile  in  multiparticulates  is  to  coat  them. Reasons for  the application of
coating  onto  multiparticulates  are  to  obtain  functional  coats,  provide  chemical
stability, improve physical characteristics and enhance patient acceptance. Coats are
formed  from  various  polymeric  coating  materials  broadly  classified  as  aqueous
polymer  dispersions,  polymer  solutions,  molten  polymers  and  dry  powders.
Depending on the type of coating material used, functions such as sustained release,
targeted release, delayed release and pulsatile release can be achieved. 
The  most  common  method  used  for  the  application  of  coating  onto
multiparticulates  is  air  suspension  coating.  Other  methods  include  compression
coating,  solvent  evaporation,  co-acervation and Interfacial  complexation. It  is  also
possible to form coated multiparticulates by spray drying and spray congealing. 
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A multiparticulate composition may allow controlled release of the drug over a
wide range of release rates and permit the release rate to be set at a predetermined
rate, such a formulation may be formed using a melt-congeal process which maintains
the crystallinity of the drug during the melt congeal process [7,8,9,10].
1.4.2 MECHANISM OF DRUG RELEASE FROM MULTI-PARTICULATES:
The mechanism of drug release from multiparticulates occurs in the following ways:
Diffusion
On  contact  with  aqueous  fluids  in  the  gastrointestinal  tract  (GIT),  water
diffuses into the interior of the particle. Drug dissolution occurs and the drug solutions
diffuse across the release coat to the exterior.
Erosion
Some  coatings  can  be  designed  to  erode  gradually  with  time,  there  by
releasing the drug contained within the particle.
Osmosis
In allowing water to enter under the right circumstances, an osmotic pressure
can be built up within the interior of the particle. The drug is forced out of the particle
into the exterior through the coating [11].
1.5 PELLETS:
Figure No: 2
Pellets  are  agglomerates  of  fine  powders  or  granules  of  bulk  drugs  and
excipients. They consist of small, free flowing, spherical or semi-spherical solid units,
typically  from  about  0.5  mm  to  1.5  mm  and  are  intended  usually  for  oral
administration. Implants  of  small,  sterile  cylinders  formed  by  compression  from
medicated masses are also defined as pellets in pharmacy. Pellets can be prepared by
many  methods,  the  compaction  and  drug-layering  being  the  most  widely  used
today[12,13,14].
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The most common advantages of Pelletization are [15,16,17,18,19,20]:
• Improved appearance of the product and the core is pharmaceutically elegant.
• Pelletization offers flexibility in dosage form design and development.
• Pellets are less susceptible to dose dumping.
• It reduces localized concentration of irritative drugs.
• It improves safety and efficacy of a drug.
• Pellets offer reduced variation in gastric emptying rate and transit time.
• Pellets disperse freely in GIT and invariably maximize drug absorption and
also reduce peak plasma fluctuation.
• Pellets ensure improved flow properties in formulation development.
• The coating of pellets can be done with different drugs to enable a controlled
release rate of the formulations.
• Pellets minimize intra and inter subject variability profiles, unlike the single
unit conventional dosage form.
• Successful film coating can be applied onto pellets due to their ideal spherical
shape and a low surface area to volume ratio.
• Pellets composed of different drugs can be blended and formulated in a single
dosage form.
• Even pellets with different release rates of the same drug can be supplied in a
single dosage form.
• Pellets can be divided into different dose strengths without formulation and
process changes.
• They can be blended to deliver different incompatible agents simultaneously.
• They provide  different  release  rates  at  same  or  different  places  of  gastro
intestinal tract.
1.5.1 PELLET FORMATION AND GROWTH: 
The mechanism of pellet formation and growth, the following steps were proposed:
• Nucleation
• Coalescence
• Layering 
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• Abrasion transfer. 
Nucleation
Nucleation is  a common stage in all pelletization/granulation processes and
occurs whenever a  powder is  wetted with liquid. The primary particles are drawn
together to form three phase air wetted liquid nuclei  and are attached together by
liquid bridges, which are pendular in nature. The bonding strength is improved by
reduction of particle size. The sizes of primary particles, moisture content, viscosity of
binding  particles,  wet  ability  of  substrate  and  the  processing  conditions,  such  as
tumbling and drying rates, influence the size, rate and the extent of nuclear formation.
Both mass and number of nuclei in the system changes as a function of time, which is
an important feature of nucleation [13,21,22].
             Nucleation followed by a transition phase and the growth mechanism
affecting the transition region are coalescence and layering.
Coalescence
              Coalescence is defined as the formation of large sized particles by random
collision of well-formed nuclei, and the mechanism requires slight excess moisture on
the nuclear surface. Although the number of nuclei is progressively reduced, the total
mass of the system remains unchanged during this step. Layering is a slow growth
mechanism and involves a successive addition of fragments and fines on an already
formed nucleus [22].
Layering
                In the layering step, the number of particles remains same but the total mass
in the system increases  due to  increasing particle  size as  a  function of  time. The
fragments or fine particles can be formed by particle size reduction that occurs due to
attrition, breakage and shatter. The fines and fragments that are produced through size
reduction  are  picked  up  by  large  pellets.  Production  of  fines  and  subsequent
coalescence and layering continues until the number of favorable coalition’s declines
rapidly, thereby leading to a reduction in the rate of growth of the pellets. [13]
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Abrasion transfer
In the ball growth phase the main mechanism affecting the slow growth of
agglomeration is the abrasion transfer which involves the transfer of material from
one  granule  formed  to  another  without  any  preference  in  either  direction.  This
situation does not result in a change in the total number or mass of the particles. The
particles however undergo a continuous change in size as long as the conditions that
lead to the transfer of material exist. [13]
Manufacturing of pellets directly from powder
                                                          Figure No: 3
Powder is mixed and moistened with a solvent or binder and the powder bed is
set  into a  centrifugal  motion (Fluid Bed Pelletizing in the rotor).  The impact  and
acceleration forces that occur in this process result in the formation of agglomerates,
which become rounded out into uniform and dense pellets. The speed of rotation has a
direct influence on density and size of the pellets. The moist pellets are subsequently
dried in the fluid bed.
Lipid/Hot Melt Coating [23]:
                                                               Figure No: 4
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Lipid/Hot melt coating is a very effective process for the application of waxes
and molten materials as protective films for manipulating the particle properties.
Glatt  offers  Fluid  Bed  Coating  (Top  Spray  Coating,  Bottom  Spray  and
Tangential Spray) as a technical solution for coating different particles and tablets.
The  coating  fluid  is  sprayed  onto  solid  materials,  which  are  presented  to  it.  The
introduction of  process air  causes  the film coating to solidify and a small  droplet
which is low viscosity ensures that the distribution is uniform. The time and energy-
intensive evaporation of solvents can be dispensed with by the use of molten materials
as coating liquids.
1.5.2 PELLETIZATION TECHNIQUES
• Powder layering
• Extrusion-Spheronization
• Compression 
• Solution/Suspension layering
• Globulation
• Balling or Spherical agglomeration
• Melt spheronization
• Cryopelletization
Powder layering[24,25]
Principle
                                                              Figure No: 5
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• It is carried out in Fluid bed Granulator or Tangential spray equipment.
• During powder layering, a binding solution and a finely milled powder are
added simultaneously to a bed of starter seeds at a controlled rate. In the initial
stages, the drug particles are bound to the starter seeds and subsequently to the
forming pellets with the help of liquid bridges originated from the sprayed
liquid.
• These liquid bridges are eventually replaced by solid bridges derived either
from a binder in the application medium or from any material, including the
drug substance, that is soluble in the liquid.
• Successive layering of the drug and binder solution continues until the desired
pellet  size is  reached. Throughout the process,  it  is  extremely important  to
deliver the powder accurately at  a predetermined rate and in a manner that
maintains  equilibrium  between  the  binder  liquid  application  rate  and  the
powder delivery rate.
• If  the powder delivery rate is  not  maintained at  predetermined equilibrium
levels, over wetting or dust generation may occur and neither the quality nor
the yield of the product can be maximized.
• Towards  the  end  of  the  layering  process,  it  is  likely  that  fines  may  be
generated  owing  to  potential  interparticle  and  wall-to-particle  friction  and
appears in the final product, there by lowering the yield.
• The  problem  can  be  overcome  if  the  application  medium  is  sprayed  on
cascading pellets at the end of layering process to increase the moisture level
at the pellet surface and facilitate layering of the fines onto the pellets.
Extrusion-Spheronization [ 26,27,28 ]
• Extrusion–spheronization  is  a  multistep  process  involving  dry mixing,  wet
granulation, extrusion, spheronization, drying and screening.
• The first  step  is  dry mixing of  the  drug and excipients  in  suitable  mixers
followed by wet granulation, in which the powder is converted into a plastic
mass that can be easily extruded.
• The  extruded  strands  are  transferred  into  a  spheronizer,  where  they  are
instantaneously broken into short cylindrical rods on contact with the rotating
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friction plate and are pushed outward to the stationary wall of the processing
chamber by centrifugal force.
• Finally, owing to gravity, the particles fall back to the friction plate, and the
cycle is repeated until the desired sphericity is achieved.
Principle of the Granulate Spheronizing Process:
Figure No: 6
Principle of the Extruded Product Spheronizing Process:
Figure No: 7
Compression:
• It is a type of Compaction technique for preparing pellets. Pellets of definite
sizes  and shapes  are  prepared  by compacting mixtures  or  blends  of  active
ingredients and excipients under pressure.
• This process can be achieved by using extrusion-spheronization technique.
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Solution/Suspension layering [29,30]:
Principle
• Layering  processes  involve  loading  solid  inert  cores  with  drugs  and/or
excipients. Inert cores are placed in a suitable vessel such as a coating pan or a
fluid bed and are layered according to different methods.
Figure No: 8
• Some  methods  consist  of  spraying  onto  the  cores  a  solution/suspension
containing both drug and binding agent. Others are based on layering the drug
directly in powder form where drug loading occurs by gravity and adhesion is
ensured by a liquid binder sprayed onto the cores.
• The  layering  process  is  particularly  suitable  for  production  of  small  drug
loaded units, multiples of which are placed into capsules for patient delivery.
• In the case of spherical inert cores such as non-pareils, the layering techniques
from solution/suspensions produce homogeneous drug loaded particles, which
retain an approximately spherical shape.
Fluidized bed Coater:
Principle:
Fluidized bed coating is a process that takes place inside a fluidized bed where
by a coat is introduced to cover the intended object in order to protect or modify its
behavior. Particulate coating is a form of fluidized bed coating involving the coating
of solid particles inside the bed. In the process, a layer is deposited onto the surface of
fluidized  solid  particles  by spraying  with  a  solution  of  the  coating material.  The
fluidizing gas is also used to dry the deposited solution to form a coat on the surface
of the particle. Fluidized beds are used for coating because of their high energy and
mass transfer. Fluidized beds for film coating can be divided into three groups.
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Types:
• Top spray
• Tangential (Rotating disk granulator) 
• Bottom spray (Wurster Process)
Fluid Bed Coating Flow Chart:
Figure No: 9
Top spray:
• This process is used for general coatings right up to enteric coating.
• With top spray coating in the fluid bed, particles are fluidized in the flow of
heated air, which is introduced into the product container via a base plate.
• The coating liquid is sprayed into the fluid bed from above against the air flow
(countercurrent)  by means of  a  nozzle.  Drying takes  place as  the particles
continue to move upwards in the air flow.
• The expansion chamber is  lengthened to allow powder to remain fluidized
longer and to move with a higher velocity, so that agglomeration is minimized.
The expansion chamber is conically shaped to allow uniform declaration of air
stream. The filter housing is larger and designed to shake the fines back into
the bed interrupting fluidization; this reduces agglomeration tendencies.
• The nozzle is positioned low in the expansion chamber so that coating material
impinge on the fluidized particle a short distance from the nozzle, this reduces
droplet spray drying and provides for longer subsequent drying of the coated
particles.
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Tangential spray:
• Ideal for coatings with high solid content.
• These techniques  have been extended for coating operations  and combined
with an expansion chamber to form the rotating disk granulator and coater
fluid bed  device.  The basic  design  employs  a  rotating disk in  the product
container.
• The disk can be moved up or down to create a variable slit opening between
the outer perimeter of the disk and the sidewall of the container. Air is drawn
into the product container through the slit under negative pressure.
• This fluidizes the material  along the circumferential  surface of  the product
container. At the same time the disk rotates at varying speeds and moves the
product by centrifugal force to outer portions where it is lifted by fluidizing air
stream into the expansion chamber.
• As the material decelerates, it descends to center of the disk and repeats the
same sequence.
• The fluidization pattern is  often described as a  spiraling helix  or  rope-like
pattern around the inside of rotor chamber. Spray nozzles can be immersed in
the  bed  of  fluidized  material  and  spray applied  in  tangential  fashion  with
respect to the particle flow.
• Very thick film layers can be applied by means of the rotor method.
Bottom spray:
• This  process  is  particularly  suitable  for  a  controlled  release  of  active
ingredients. In the Wurster process, a complete sealing of the surface can be
achieved with a low usage of coating substance.
• Inside  the  container  a  second  cylinder  (coating  partition)  which  is  raised
slightly  above  the  perforated  plate,  centered.  Below  this  partition  a  spray
nozzle used to dispense the coating solution is fitted in the base plate resulting
in a spray pattern that is concurrent with the air feed.
• The perforated plate is designed with large holes in the area under the coating
partition and smaller holes in the remainder of the plate, except for one ring of
large holes at the perimeter.
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• The  design  allows  the  substrate  particles  to  be  pneumatically  transported
upward through the coating partition and downward outside this partition.
• By using a wurster cylinder and a base plate with different perforations, the
particles to be coated are accelerated inside the wurster tube and fed through
the spray cone concurrently.
•
 As the particles continue travelling upwards,  they dry and fall outside the
wurster tube back towards the base plate. They are guided from the outside
back to the inside of the tube where they are once again accelerated by the
airflow. This produces an extremely even film coating. Particles of different
sizes are evenly coated.
             
Figure No: 10
 Globulation
• Spray drying is  the process  in  which drugs  in  the form of  suspension or
solution without excipients are sprayed in to a hot stream to produce dry and
more spherical  particles.  This process is commonly used for improving the
dissolution rates, hence bioavailability of poorly soluble drugs. [31] 
•
 Spray congealing is the process in which a drug is allowed to melt, disperse
or dissolve in hot melts of gums, waxes or fatty acids and is sprayed in to an
air  chamber  where  the temperature  is  kept  below the melting point  of  the
formulation  components,  to  produce  spherical  congealed  pellets.  Both
immediate  and  controlled  release  pellets  can  be  prepared  in  this  process
depending  on  the  physiochemical  properties  of  the  ingredients  and  other
formulation variables. [32]
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Balling or Spherical agglomeration
• It  is  the pelletization process  in  which pellets  are  formed by a continuous
rolling and tumbling motion in pans, discs, drums or mixtures. 
• The process consists of conversion of finely divided particles in to spherical
particles upon the addition of appropriate amounts of liquid. 
Liquid induced
• Liquid is added to the powder before or during the agitation step. As powders
come in contact with a liquid phase, they form agglomerates or nuclei, which
initially are bound together by liquid bridges.
• These are subsequently replaced by solid bridges, which are derived from the
hardening binder or any other dissolved material within the liquid phase. The
nuclei formed collide with other adjacent nuclei and coalesce to form larger
nuclei or pellets. 
Melt induced
• It is similar to liquid-induced processes except that the binding material is a
melt. Therefore,  the pellets are formed with the help of congealed material
without having to go through the formation of solvent-based liquid bridges.
[33,34]
Tumbling melt granulation
• A powdered mixture of meltable and non-meltable materials is fed onto the
seeds in a fluid-bed granulator.
• The mixture adheres onto the seeds with the binding forces of a melting solid
to form the spherical beads. 
• In  preparing  the  spherical  beads,  both  viscosity  and  particle  size  of  the
meltable materials should be kept at an optimum value. 
• The  particle  size  of  a  meltable  material  should  be  1/6  or  lower  than  the
diameter  of  the  seeds.  High-viscosity  meltable  materials  should  not  be
employed  to  avoid  agglomeration  of  seeds  and  producing  beads  of  low
sphericity. [35,36]
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Cryopelletization
• Cryopelletization is  a  process  whereby droplets of a  liquid formulation are
converted into solid spherical particles or pellets by using liquid nitrogen as
the fixing medium. 
• The procedure permits instantaneous and uniform freezing of the processed
material owing to the rapid heat transfer that occurs between the droplets and
liquid nitrogen. The pellets are dried in conventional freeze dryers. [37,38]
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2. LITERATURE REVIEW
Kotta  Kranthi Kumar  et  al.,  designed  and evaluated multi  particulate  system of
extended  release  indomethacin  capsules  USP.  By  pellatization  method:  The
indometahcin is coated on inert  sugar  spheres by using povidoneK-30 as a binder
solutions  and  Hydroxypropyl  methylcellose,  Ethyl  cellose  coating  agents  used  for
extended release action. The prepared capsules were evaluated for content uniformity
weight variation, in-vitro disintegration time, assay, and in-vitro drug release study.
All the formulation exhibited assay,  content uniformity with in the range given in
USP[39].
S.  Eskandari et  al.,  developed  an  extended  release  pellet  formulation  of
indomethacin by the centrifugation (rotary fluid bed granulation) or powder layering
method. Layered, nonpareil pellets composed of sugar, Avicel PH 101 and lactose by
using FREUND CF granulator and were treated by a binder solution (HPC-L) applied
by spray gun. The amount of Eudragit NE 30 D, Opadray and SDS in coating solution
adjusts  release  of  the  pellets.  It  would  be  possible  to  maintain  a  constant  anti-
inflammatory serum concentration of indomethacin by ingestion of only one unit dose
every 12 hours, and reduce the gastrointestinal disturbances [40].
Kar S K et al.,  reported  controlled release preparations to reduce the gastro irritant
and ulcerogenic effects of non-steroidal anti-inflammatory drugs. A develop matrix
tablet-based controlled release formulations of Indomethacin, using ethyl cellulose as
the rate-controlling polymer.  In  order  to  prevent  initial  release  of  the  drug in  the
acidic environment of the stomach, cellulose acetate phthalate was incorporated in the
matrix in varying amounts. The combination of cellulose acetate phthalate with ethyl
cellulose in the matrix base can be an effective means of developing a controlled
release  formulation  of  indomethacin  with  very  low  initial  release  followed  with
controlled release up to 14-16 hours [41].
P.A.  Elchidana  et  al.,  developed  Indomethacin  extended  release  formulation  by
pelletization  using  the  method  of  extrusion/  spheronization.  The  drug  containing
pellets were further coated to achieve the required release profile as per USP. Coating
systems developed on the principle of microporous membrane drug delivery using
soluble salt gave the best results [42].
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Mircea hirjau  et al.,  produced and characterized pellets containing a non steroidal
anti-inflamatory  (NSAID)  drug,  coated  with  an  entric  polymer  by  extrusion-
spheronization using microcrystalline cellulose (Avicel PH 101) as a spheronization
aid,  polyvynilpyrrolidone  K30 as  a  binder  and  lactose  as  filler.  The  pellets  were
analysed for the following physical parameters, relevant for subsequent processing of
the  pellets:size  distribution,  circularity,  bulk  density.  The  pellets  have  shown
characteristics suitable for hard capsule filling [43].
A. Akhgari  et al.,  evaluated the effect of two factors (ratio of Eudaragit S100 and
Eudaragit L100 and the coating level) on indomethacin release from pellets. Coating
formulations were designed on the full factorial design. In the ratio of Eudaragit S100:
Eudaragit L100 (1:4, 1:1 and 1:0) and the level of coating (10%, 15%, 20% w/w)
respectively.  Polymers  were  coated  onto  the  pellets  containing  20%  (w/w)
indomethacin, using a fludized bed coating apparatus. Dissolution test was carried out
in media with different pH (1.2, 6.5, 6.8 and 7.2). The dissolution data revealed that
the level of coating and the ratio of polymers are very important to achieve optimum
formulation [44].
M. A. Hull  et al., suggested the non-steroidal anti-inflammatory drug indomethacin
has  anti-colorectal  cancer  activity.  Although  indomethacin  itself  has  significant
adverse effects, including serious upper gastrointestinal toxicity, the development of
novel  derivatives  that  may  have  an  improved  safety  profile  means  that  further
investigation of the anti-colorectal cancer activity of indomethacin is warranted [45].
Shun  Por  Li  et  al.,  prepared  indomethacin  pellets  by  spraying  slurry  of
indomethacin,  EudragitB  5-100,  dibutyl  sebacate  and  alcohol  onto  an  appropriate
mesh  fraction  of  nonpareil  seeds  using  appropriate  processing  equipment.  The
average particle diameter and the overall particle size distribution of the indornethacin
powder were found to be critical  factors influencing the physical  properties of the
pellets. Micronized indomethacin powder, having an average particle diameter of four
microns and a particle size distribution ranging from one to thirteen microns,  was
found to be the optimum for this layering process. The layering process was found to
greatly affect the release characteristics of the drug from the beadlets [46].
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Shan-Yang Lin et al., estimated the influence of ethyl cellulose (EC) with different
viscosity  grades  on  in  vitro  drug  release  from  EC  matrix  tablets  containing
Indomethacin. Four viscosity grades of EC (7, 10, 50 and 100 cp) were used. The
drug  release  from  Indomethacin  tablets  marginally  increased  with  an  increase  in
viscosity grade. The viscosity grade effect on release rates would be differences in
tablet porosity [47].
A. Mesnukul et al., studied the carrier system could effectively enhance the solubility
of  indomethacin  and  an  addition  of  xanthan  gum  could  sustain  the  drug  release.
Eudragit  L100 film coating could protect the carrier not to be disturbed with HCL
buffer  pH 1.2 and could dissolve in  phosphate buffer  pH 6.2,  therefore,  the drug
release from coated tablet was initially very low but subsequently gradually released
and prolonged in phosphate buffer pH 6.2[48].
H. Lippold et al., developed guaiphenesin pellets are coated in a fluidized bed with
aqueous ethyl cellulose dispersions (Aquacoat ECD-30) containing different amounts
of  dibutyl  sebacate  (DBS)  as  plasticizer.  Optimal  film  formation  and  zero-order
release rates are obtained if the produced microcapsules (MC) are treated with heat
about 10°C above the minimum film forming temperature (MFT).  At 25oC of the
release medium the coats of the MC with a MFT of 40-50oC are in the glassy state,
thus the permeability is extremely low [49].
Andrei Dashevsky et al., prepared a rupturable, capsule-based pulsatile drug delivery
system with pH-independent properties by using aqueous coating. The drug release is
induced by rupturing of the top-coating, resulting by expanding of swellable layer
upon water penetration through the top-coating. A higher coating level was required,
when  aqueous  dispersion  was  used,  compared  to  organic  coatings.  However,  an
advantageous aspect of the aqueous coating was the lower sensitivity of the lag time
to a deviation in the coating level [50].
.
P. B. Deasy  et al., developed two new pelletized formulations of indomethacin and
compared  against  pellets  from  the  proprietary  product,  Indocid-R.  Extensive
dissolution testing involving pH-shift and topographical profiling showed that the new
product containing polyvinyl pyrrolidone had slightly faster in vitro release than the
commercial product, but the other new product containing sodium lauryl sulphate had
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reduced drug release. However, on in vivo testing in dogs, the new product containing
sodium  lauryl  sulphate  had  the  highest  bioavailability  of  the  three  preparations
examined due to its effect as a penetration enhancer [51].
Mundada .AS et  al., investigated for  sustaining the  drug release  from pellet  by using
Diclofenac sodium (10% w/w) as a model drug by extrusion and speronization. The drug
containing pellets were coated using DB plasticized film-coating solutions. Films prepared
from novel biomaterial with 20% and 30% w/w plasticizer concentration [52].
Nantharat  Pearnchob  et  al., studied  the  film  forming  ability  of  ethylcellulose
powder and the effect of formulation factors (plasticizer type and concentration) and
curing  conditions  (curing  temperature  and  time). Although ethylcellulose-coated
pellets had an uneven surface, extended drug release could be obtained with coating
level of 15%. Because of its high glass transition temperature, ethylcellulose-coated
pellets showed unchanged drug release profiles upon storage at room temperature for
3 years [53]. 
 M. Anand Kumar et al., formulated Tamsulosin Hcl extended release pellets using a
combination  of  ethyl  cellulose  N-50  and  Eudragit  L-100  as  a  coating  material.
Initially  trials  were  done to  optimize  the  drug  loading on  to  sugar  pellets  for  its
uniformity of  size and Assay,  varying  the concentration  of  HPMC E-5 as  binder,
Aerosil as lubricant and sodium starch glycollate as disintegrant. The release study at
2, 3, 5 and 8 hours were the target responses and were restricted to 13-34%, 47-68%,
NLT 70%, NLT 80% respectively.  The optimal coating formulation was achieved
with Eudragit L-100 9% of the weight of the drug loaded pellets and ethyl cellulose
N-50 with 25% of the Eudragit L-100 content. The drug release from the optimized
pellets  was  compared  with  the  Innovator  product  FLOMAX  capsule  showed  the
similarity factor (F2) of 76.43[54].
KHAN  M.  S et  al.,  prepard  and  evaluated  microporous  pellets  loaded  with
Indapamide  (IP)  using  blend  of  Avicel  PH  101  (Microcrystalline  cellulose)  and
sodium chloride (Nacl) by extrusion/ spheronization technique for controlled release.
Solid, discrete, reproducible pellets were obtained. Sieve analysis data indicated that
the size of prepared pellets were in the range of 1135µm to 1245µm. Prepared pellets
were spherical in shape, have dent surfaces with pores on the surface, as evidenced by
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scanning electron microscopy (SEM). The optimized formulation F3 showed 91.41 %
drug release up to 24 hours. The stability studies showed no significant difference in
drug content. The drug release performance was greatly affected by the polymer and
pore forming agent used in preparation of pellets [55].
Nisar-Ur-Rahman et al., developed controlled release diltiazem pellets with Eudrgit
NE40 and the effects of percent drug layering, pH and stirring speed of dissolution
media on drug release were also evaluated. The release profile of coated pellets was
found to be inversely proportional to the thickness of the polymer coat and desirable
controlled  release  characteristics  could  be  achieved  by  manipulating  the  coating
levels. The percent drug layering onto inert pellets had no effect on the release rate of
coated pellets. Moreover, diltiazem HCL release was fairly independent of pH [56].
S. Muschert et al., to elucidated the drug release mechanisms in pellets coated with
aqueous ethyl cellulose dispersion, providing long term stable drug release profiles
and  containing  different  types  of  starter  cores.  DiltiazemHCl  release  from pellets
coated  with  ethyl  cellulose  containing  small  amounts  of  poly(vinyl  alcohol)-
poly(ethylene  glycol)  graft  copolymer  is  primarily  controlled  by  drug  diffusion
through the intact polymeric membranes[57].
Mustafa  Sinan  Kaynak  et  al.,  formulated  of  controlled  release  Glipizide
incorporated into non-pareil  seeds by spraying glipizide in a solution in methylene
chloride  containing polyvinyl  pyrolidone  (PVP 30K) as  a  binder  and  talc  as  anti
sticking agent Upper layer coating was Eudragit RS 100 PM and Eudragit RL 100 PM
polymers were used which provide the release of the active ingredients independent of
pH of the environment. The amount of the coating solution is inreased, the release of
glipizide was significantly prolonged. The dissolution profiles of the manufactured
pellets were evaluated in pH 7.4 phosphate buffer solution in USP apparatus [58].
Rakhee A. Surana et al., formulated Phenyl propanolamine hydrochloride sustained
release  pellets.  Uni Glatt  fluid  bed processor  (Glatt,  Germany)  was used for  drug
solution layering and also for sustained release coating. By using hypromellose E5,
ethylcellulose  10cps and ethylcellulose 45cps polymers  in  combination.  Polymeric
solution  was  prepared  by  dissolving  polymers  into  different  solvents  in  different
proportion to form clear coating solution. The pellets were evaluated for appearance,
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shape  and  size  analysis,  density,  assay,  content  uniformity,  in-vitro  drug  release
studies,  stability study and kinetic study.  The optimized batches  were charged  for
stability at 40°C and 75% RH for 2 months. The drug release studies were repeated
after storage for 2 months at conditions like room temperature (RT) and 40ºC and
75% RH [59]. 
N. A.  Muhammad  et  al., studied  the  release  of  a  water  soluble  drug  in  various
dissolution  media  from  pellets  coated  with  HPMCP  50  with  30%  plasticizer
containing  various  levels  of  hydroxyl  propylcellulose  (HPC)  or  HydroxyPropyl-
MethylCellulose (HPMC), HPMCP 50 alone without a plasticizer does not form a
film.  Drug  release  from  coated  pellets  was  found  to  be  ІІ50.  Drug  release  was
increased as the percentage of HPC was increased. Higher release rates were obtained
with HPMC compared to HPC. Coating level significantly influenced drug release in
0.06 N HCL; however, less of an effect was observed at pH 5.5 [60].
P. K. Lakshmi et al., formulated Duloxetine hydrochloride enteric coated pellets using
fluidized bed. Three separate layers, the drug layer, the barrier layer and the enteric
layer were coated onto the inert core pellets. Various other properties such as surface
morphology,  bulk  and  tapped  density,  hausner´s  ratio,  yield  of  pellets,  moisture
content and particle size distribution were also studied in the optimized pellets [61]. 
D. Yadav et al., developed and evaluated time dependent rupturable multiparticulate
pulsatile delivery system for glipizide. Microcrystalline cellulose (MCC) based pellets
containing  glipizied  were  prepared  by  extrusion-spheronization  technique  (Type  1
pellets)  coated  with  two  consecutive  layers,  a  swellable  layer  of  hydroxyl-
propylmethyl cellulose (HPMC) and a rupturable layer of plasticized ethylcellulose
(EC) with fluidized bed coating. Drug release and water uptake studies were carried
out on formulated pellets [62]. 
A.  Kramar  et  al., evaluated  three  formulation  parameters  for  the  application  of
polymethacrylic  films from aqueous dispersions in order  to obtain multiparticulate
sustained  release  of  diclofenac  sodium.  In  this  film  coating  of  pellet  cores  was
performed  in  a  laboratory  fluid  bed  apparatus.  To  influenced  on  plasticizer
concentration on the drug release from the pellets [63]. 
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S.  K.  Singh  et  al., developed  delayed  release  micropellet  dosage  form  for
Lansoprazole.  Drug-Excipient  compatibility  data  and  prototype  formulations,  the
formula that found to be giving the desired drug release pattern was considered as the
optimized formulation  showed delayed  release  profile  and  it  was  within the  USP
limits,  and  also  this  formulation  done  by  FBC  process  which  is  a  sophisticated
method[64].
M.  Korber  et  al., evaluated  strategies  to  set-off  the  very  strong  pH-dependent
solubility (solubility: 80 mg/ml at pH 2 and 0.02 mg/ml at pH 7.5, factor 4000) of a
mesylate  salt  of  weakly  basic  model  drug  (pKa  6.5),  in  order  to  obtain  pH-
independent  extended drug release.  The incorporation of  an enteric  polymer  layer
underneath the EC/HPC coating decreased the free base formation at pH 7.5 and thus
resulted in a more complete release of up to 90% of the drug loading over 18 hours.
The release enhancing effect was attributed to an extended acidification through the
enteric polymer layer [65].
F. Siepmann et al.,  used blends of aqueous dispersions of a water-insoluble and an
enteric  polymer,  namely  ethylcellulose  :  hydroxypropyl  methylcellulose  acetate
succinate  (EC:HPMCAS)  and  ethyl  cellulose:methacrylic  acid  ethyl  acrylate
copolymer (EC:EudragitRL), as coating materials to control theophylline release from
matrix pellets. Varying the polymer blend ratio, broad ranges of drug release patterns
were obtained at low as well as at high pH. The release profiles were rather similar for
both types of blends in 0.1 M HCl, where as significant differences were observed in
phosphate  buffer  pH  7.4  and  the  drug  release  at  high  pH  was  much  slower  for
EC:HPMCAS  blends  compared  to  EC:EudragitRL  blends,  although  HPMCAS
leached  out  more  rapidly  (and  to  a  higher  extent)  from  the  film  coatings  than
EudragitRL. The EC structures remaining upon HPMCAS leaching are mechanically
stronger  and  drug  release  is  controlled  by  diffusion  through  the  polymeric
remnants[66].
G.J.  Vergote  et  al.,  developed  controlled  release  pellet  formulation  using  a
nanocrystal  colloidal  dispersion  of  ketoprofen  process  the  aqueous  nanocrystal
colloidal dispersion into a hydrophobic solid dosage form a spray drying procedure
was  used.  The  in  vitro  dissolution  profiles  of  wax  based  pellets  loaded  with
nanocrystalline ketoprofen are compared with the profiles of wax based pellets loaded
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with microcrystalline ketoprofen and of a commercial  sustained release ketoprofen
formulation. The surfactants used to increase the dissolution rate were either added
during  the  production  process  of  the  nanocrystal  colloidal  dispersion  (sodium
laurylsulphate) or during the pellet manufacturing process (Cremophor RH40) [67].
J. J. Sousa  et al., studied the different  ways in which water can be considered an
active excipient in terms of the amount used to obtain the wet mass, the dispersion
within the mass and the drying process. Physical characteristics of the pellets were
analyzed for pellets within the same fraction size of 1-1.4 mm diameter. The analysis
indicated that the amount of water and the extrusion and drying processes are of great
importance and influenced the physical characteristics of the resultant pellets. Hence,
water should be considered as an 'active' excipient rather than an inert component of
the extrusion masses [68].
S. Muschert et al., studied the drug release mechanisms from aqueous ethylcellulose-
coated  pellets  containing  different  types  of  drugs  and  starter  cores.  Theophylline,
paracetamol, metoprolol succinate, diltiazem HCL and metoprolol tartrate were used
as model drugs exhibiting significantly different solubilities (e.g. 14, 19, 284, 662 and
800 mg/ml at  37 °C in 0.1 N HCL).  Drug release was found to be controlled by
diffusion through the intact polymeric membranes, irrespective of the drug solubility
and type of core formulation. The ethylcellulose coating was dominant for the control
of drug release, minimizing potential effects of the type of pellet core and nature of
the surrounding bulk fluid, e.g. osmolality. Thus, this type of controlled drug delivery
system can be used for very different drugs and is robust [69].
N. Vyas  et al., to developed ER formulations of a practically insoluble macrolide
antibiotics clarithromycin suitable for once-a-day oral administration. The polymers
carbopol 71G, low-viscosity (LV) hypromellose, polyox 750N, hypromellose K4M as
well as LV-ethylcellulose (EC) interspersed with pore-formers like Klucel LF and LV
hypromellose.  The  formulation  comprised  of  drug  granulated  and  tableted  with
commonly employed tableting aids like MCC, talc, lactose, colloidal silicon dioxide
and magnesium stearate [70].
Sandhiya.  K.  M  et  al., formulated  the  oral  sustained  release  matrix  tablets  of
Ambroxol HCl in order to improve efficacy, reduce the frequency of administration
and better patient compliance. Differential scanning calorimetric analysis confirmed
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the  absence  of  any  drug  polymer  interaction.  Matrix  tablets  of  Ambroxol
Hydrochloride  were  formulated  employing  hydrophilic  polymers  HPMC  K100M,
Carbopol  934P  and  hydrophobic  polymer  Ethyl  cellulose  as  release  retardant
polymers.  Matrix tablet  containing Ethyl  cellulose (F7) formulation were found to
show good initial release 24.24% at 2 hrs and at the end of 12 hrs the drug release was
found to  be 96.86%. The n value for  F7 obtained from Korsmeyer-peppas model
confirmed that the drug release was anomalous diffusion mechanism [71].
Siddaramaiahb  et al., developed Theophylline by the pelletization technique using
the extrusion/spheronization method. The drug-containing pellets were further coated
to  achieve  the  required  release  profile.  The  different  polymeric  coatings  of  ethyl
cellulose (EC), hydroxy propyl methyl cellulose (HPMC) and Eudragit S-100 were
used. From that coated pellets were characterized with regard to the percentage yield,
density, friability, sphericity, drug entrapment efficiency and size distribution. Coated
drug  pellets  were  further  characterized  by  Fourier  transform  infrared  (FTIR)
spectroscopy. Drug release profiles were studied for uncoated pellets, pellets coated
with plain polymer and pellets coated with polymeric containing the pore-forming
agent, SLS. The in vitro drug release revealed that formulation B4 had the expected
release profile (24 hrs releases). The optimized formulation is an ideal formulation for
once-a-day administration [72].
George  Reyes  et  al., investigated  the  application  of  an  aqueous  ethylcellulose
dispersion (Surelease)  as a wet granulation agent (release retardant binder),  on the
release of theophylline from extended release (ER) inert matrix tablets. The influence
of varying polymer concentration, filler choice and compression force on drug release
profiles were studied [73].
H.  Kranz et  al.,  identified  an  efficient  tool  to  adjust  drug  release  patterns  from
aqueous  and  organic  ethylcellulose  (a  gastrointestinal  insoluble  polymer)  coated
pellets and to evaluate the long term stability of the film coatings. The drug release
rates  from organic  coated  ethylcellulose  :  Kollicoat  MAE 100 P  pellets  stored  at
ambient and stress conditions did not change which could be explained by differences
in  the  film  formation  process.  The  addition  of  methacrylic  acid/ethyl  acrylate
copolymer  to  ethylcellulose  film coatings  in  combination with an  organic  coating
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process  is  able to  achieve  broad ranges  of  drug release patterns  and to overcome
storage instability [74].
Raghavendra rao N. G  et  al., developed of rapidly disintegrating oral  tablets by
direct  compression  using  co-grinding and  solid  dispersion  methods  by  using
chlorthalidone as a model drug. The solid dispersions and co-grinding method were
followed to increase solubility and bioavailability. The tablet formulation containing
polyvinyl pyrrolidone K-12 solid dispersion showed maximum drug release than the
chlorthalidone polyvinyl  pyrrolidone K-12 co-grinding method. Solid dispersion of
the  drug  with  the  hydrophilic  carrier  poly  vinyl  pyrrolidone  can  enhance  the
dissolution rate of chlorthalidone tablets [75].
P. Subhash Chandra Bose et  al., prepared floating tablets of diltiazem HCl using
xanthan gum as carrier by direct compression technique using PVP K-30 as a binder
and sodium bicarbonate for development of CO2 [76].
Fars K. Alanazi et al., prepared albendazole microparticles with hydrophilic polymers
such  ashydroxypropyl  methylcellulose  (HPMC),  polyvinyl  alcohol  (PVA),  and
polyvinyl pyrrolidone (PVP) using spray drying technique. The highest dissolution of
ABZ was obtained with HPMC in 1:1 ratio and with both PVA and PVP in ratio of
1: 4 microparticles. The transformation of ABZ from crystalline to amorphous state
by spray drying and the hydrophilic coating of drug particles by the polymers  are
considered  among  the  factors  which  contributed in  improvement  of  ABZ
dissolution[77].
Chowdary K. P. R et al., evaluated starch phosphate a new modified starch, PVP K-
30 and PEG 4000 as carriers in solid dispersions for enhancing the dissolution rate
and efficiency of etoricoxib, a BCS class II drug. Hence addition of PVP and PEG
4000 to  the solid  dispersions in starch phosphate is  recommended to enhance  the
dissolution rate of etoricoxib, a BCS class II drug [78].
G. Ashwini  Kumar  et  al.,  developed  a  modified  release  capsules  of  mebeverine
hydrochloride  which  are  designed  to  controlled  release  action.  Modified  release
capsules  of  mebeverine  hydrochloride  were  formulated  by  using  the  pelletization
process by drug layering on inert sugar pellets by using PVPK-30 as binder. The drug
layered pellets were coated by using the Eudragit L-100 and P.E.G-6000 as a first
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coating material by using I.P.A and water as solvents. The coated pellets were again
coated by using the Ethyl  cellulose N-50, P.E.G-6000, I.P.A and water as coating
material to sustain the drug release.  The coated pellets size and shape is observed
during processing. The coated pellets is filled in capsules No.2 and these capsules was
evaluated  for  assay,  weight  variation,  content  uniformity,  lock  length,  moisture
content, disintegration and in-vitro dissolution tests and these was with in the range.
There  is  no  physicochemical  interaction  between  drug  and  excipients  and  the
compatibility study is carried out for four weeks at different temperature conditions.
The coating step is divided into two steps for getting the desired release rate [79].
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3. AIM OF WORK
               Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) commonly
used  for  the  reduction  of  pain  and  inflammation  caused  by  condition  such  as
osteoarthritis, gout, ulcerative colitis, colon cancer. Its biological half-life is 4.5 hrs.
              When given conventionally it gets released in the upper GIT there by causing
irritation and ulcer in the upper GIT. The dosage form should be designed in such a
way that it  should minimize or prevent  drug release in the acidic environment of
upper GIT and start releasing the drug in a controlled manner once it  reaches the
alkaline environment of small intestine.
              Aim of the present work is to formulate the indomethacin pellets to present it
in the form of capsules (Extended release pellets).To develop and over an extended
period of time in the gastro intestinal  track and compared the in-vitro dissolution
profile with that of the marketed product.
OBJECTIVES:
• Reduced frequency of dosage form
• Improved patient compliance
• Maximizing bio availability with a minimum dose 
• To study the release profile of the formulation using various polymer 
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4. PLAN OF WORK
The present approach was made to formulate the Indomethacin extended 
release pellets and evaluation.
The stages involved in the plan of work are as follows:
1. Preformulation studies of drug
        a. Raw material analysis of indomethacin
        b. Drug-Excipient compatibility study
        c. Physical observation
        d. Construction of calibration curve by UV spectrophotometer
        e. FTIR study
        f. Particle size analysis
2. Formulation of extended release pellets
• Drug layering
• Extended release coating
3. Evaluation of pellets
• Bulk density
• Tap density
• Compressibility index (Carr’s index)
• Hausner ratio
• Content uniformity
• Weight variation
• Percentage yield
• Capsule lock length
• LOD (Loss on drying) of the pellets
• In vitro drug release
• Investigation of drug release kinetics
• Comparative in vitro drug release studies with market sample
• Stability study for selected formulation
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5. LIST OF MATERIALS AND EQUIPMENTS
Table No.1: List of materials used
  S. NO              MATERIALS
                   NAME OF THE
                      COMPANY
      1 Indomethacin Fabbrica Italiana Sintetici, Italy. 
      2 Ethyl  cellulose (4cps) Colorcone Asia Ltd, Mumbai.
      3 Sodium lauryl sulfate Cognis, Germany.       
      4 Hydroxy propyl cellulose Hercules, China.
      5 Povidone-K30 Zhangzhou Huafu Chemicals co.,Ltd. 
China.
      6 Low substituted Hydroxy propyl
Cellulose
Herculus, China.
      7 Talc Luzenac Val Chisone, Italy.
      8 Sugar spheres(500-600µm) Wemer-GmbH.co.KG, Germany.
      9 Isopropyl alcohol Merck (HPLC grade), Mumbai.
     10 Empty Hard Gelatin
Capsule Shell
Associated capsules Pvt.Ltd., Mumbai.
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Table No.2: List of equipments used
 
  S.NO            MATERIALS
            NAME OF THE
               COMPANY
     1 Glatt particle coater 
granulator(GPCG1.1)
Pam glatt, Mumbai.
     2              Dissolution test apparatus Electrolab, Mumbai, India.
     3 Single pan electronic digital 
Balance
Mettler Toledo, Switzerland.
     4 Tap density apparatus Electrolab  ETD-1020, Mumbai, 
India.
     5 Sieves Gotsons.
     6 pH meter Mettler Toledo, Switzerland.
     7      UV-Visible
 Spectrophotometer
(UV pharma spec 1700)
Shimadzu-corporation, U.S.A.
     8 Vernier calipers Mitutoyo corp. Japan.
     9 Mechanical stirrer REMI motors Ltd, Maharashtra.
    10 Automatic capsule filling 
Machine
Zhejiangn Fuchang machinery
co.,Ltd. China.
    11 Peristalic pump Pam glatt, Mumbai.
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                            6. DRUG & POLYMER PROFILE
6.1 Drug Profile
Indomethacin[80,81,82,83]
Structural formula
Chemical name 1-(4-Chorobenzoyl)-5-methoxy-2-methyl-
1H-indole-3-acetic acid
Molecular formula C19H16CINO4
CAS No. 53-86-1
Molecular weight 357.8
Melting point 158-162°C
Functional categories An anti-inflamatory, analgesic  agent
Description A white to yellow-tan powder
Solubility Practically insoluble in water, soluble 1 in 
50 of ethanol, 1in 30 of chloroform, and 1 
in about 40 of ether, soluble in acetone
Standards Indomethacin contains not less than 98.0
per cent and not more than 101.0 per cent
of C19H16CINO4, calculated with reference
to the dried substances 
Storage Store in well-closed, light-resistant containers
Indication:-
        Clinical indications for indomethacin include
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 Rheumatoid arthritis
 Ankylosing arthritis
 Arthritic gout
 Osteoarthritis
 Juvenile arthritis
 Psoriatic arthritis
 Reactive arthritis
 Colonic cancer
 Inflammatory bowel disease
Mechanism of action:
Indomethacin  is  a  non-selective  inhibitor  of  cyclo-oxygenase  (COX)  1  and  2,
enzymes that participate in prostaglandin synthesis from arachidonic acid. Prostaglandins
are hormone-like molecules normally found in the body, where they have a wide variety
of effects, some of which lead to pain, fever, and inflammation. Prostaglandins also cause
uterine contractions in pregnant women. Indomethacin is an effective tocolytic agent, able
to  delay  premature  labour  by  reducing  uterine  contractions  through  inhibition  of  PG
synthesis in the uterus and possibly through calcium channel blockade.
Indomethacin has two additional modes of actions with clinical importance:
     
 It inhibits motility of polymorphonuclear leukocytes, similar to colchicines
 It  uncouples  oxidative  phosphorylation  in  cartilaginous  mitochondria,  like
salicylates
These  additional  effects  account  as  well  for  the  analgesic  and  anti-inflammatory
properties.
Pharmacokinetics
Indomethacin is rapidly and almost completely absorbed from the gastrointestinal
tract after oral ingestion. The peak concentration in plasma is attained with in 2 hrs in the
fasting subject but may be somewhat delayed when the drug is taken after meals. The
concentration in plasma required for an anti-inflammatory effect have not been definitely
determined but probably less than 1µg/ml. Indomethacin is 90% bound to plasma proteins
and also extensively bound to tissues.
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Indomethacin  is  subject  to  considerable  enterohepatic  circulation.  Metabolic
reaction include O-demethylation, N-deacetylation, and glucuronic acid conjugation, the
major metabolites being desmethyl Indomethacin (DMI), and desmethyldeschlorbenzoy
Indomethacin  (DMBI)  and  their  glucuronides.  These  substances,  together  with
unchanged indomethacin and its glucuronide, are excreted in both the urine (up to about
60% of the dose in 48 h) and the feces (up to about 30% of the dose in 96 hrs) in variable
amount. Expressed as a percentage of the dose,  the average amounts excreted in the
urine  in  48 hrs  are:  unchanged  Indomethacin  5  to  20% (dependent  on  urinary  pH),
Indomethacin glucuronide 6 to 26%, DMI and its glucuronide 8 to 23%, DBI and its
glucuronide 4 to 20%, DMBI and its glucuronide less than 3%, in the feces the major
metabolites found are DMBI (up to about 16%) and DMI (up to about 12%), with only
small amont of unchanged Indomethacin and DBI.
Adverse effects
Since Indomethacin inhibits both COX-1 and COX-2, it inhibits the production of
prostaglandins  in the stomach and intestine which maintain the mucous lining of the
gastrointestinal tract. Indomethacin, therefore, like other non-selective COX inhibitors,
can  cause  peptic  ulcers.  The ulcers  can  result  in  serious  bleeding and/or  perforation
requiring hospitalization of the patient. Indomethacin also reduces plasma rennin activity
and aldosterone levels, and increases sodium and potassium retention. It also enhances
the effects of vasopressin. Together these may lead to:
 Edema (swelling due to fluid retention)
 Hyperkalemia (high potassium levels)
 Hypernatremia (high sodium levels)
 Hypertension (high blood pressure)
The drug may also cause elevations of serum creatinine and more serious renal
damage  such  as  acute  renal  failure,  chronic  nephritis  and  nephritic  syndrome.  These
conditions also often being with edema and hyperkalemia.  Additionally,  indomethacin
quite often causes headache (10 to 20%), sometimes with vertigo and dizziness, hearing
loss, tinnitus, blurred vision (with or without retinal damage) and worsens Parkinson’s
disease,  epilepsy,  and psychiatric  disorders.  Cases of  life-threatening shock (including
angioedema,  sweating,  severe  hypotension  and  tachycardia  as  well  as  acute
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bronchospasm), sever or lethal hepatitis and severe bone marrow damage have all been
reported. Skin reactions and photosensitivity are also possible side effects.
Contraindications
            
• Concurrent peptic ulcer, or history of ulcer disease
• Allergy to indomethacin, aspirin, or other NSAIDS
• Patients with nasal polyps reacting with an angioedema to other NSAIDS
• Children under 2 years of age (with the exception of neonates with patent
ductus arteriosus)
• Severe pre-existing renal and liver damage
• Caution: preexisting bone marrow damage (frequent blood cell counts are
indicated)
• Caution:  bleeding  tendencies  of  unknown origin  (indomethacin  inhibits
platelet aggregation)
• Caution:Parkinson´s disease,  epilepsy,  psychotic disorders (indomethacin
may worsen these conditions)
Dose
             Orally, 50 to 200 mg daily, in divided doses, with food. As suppositories 100 mg
at night and in the morning if required. Maximum combined oral and rectal dose, 150 to
200 mg daily.
6.2 Polymers profile
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6.2.1 Ethyl cellulose [84]
1. Non proprietary Names:
• BP         :Ethyl cellulose
• USPNF : Ethyl cellulose
2. Synonyms    : Ethocel, Surelease
    3. Chemical name CAS Registry number: Cellulose ethyl ether [9004-57-3]
   
    4. Empirical Formula and Molecular Weight: C12H23O6
    5. Structural formula:
    6. Description: Ethyl cellulose is a tasteless free flowing white to lighten colored.
    7. Application in pharmaceutical formulation and technology
The  main  use  of  ethyl  cellulose  in  oral  formulations  is  as  a  hydrophobic
coating agent for tablets and granules or pellets. Ethyl cellulose coatings are used to
modify the  release  of  a  drug,  or  to  improve  the  stability  of  a  formulation.  Ethyl
cellulose, dissolved in an organic solvent or solvent mixture, can be used on its own
to  produce  water-insoluble  films.  Higher-viscosity  ethylcellulose  grades  tend  to
produce stronger and more durable films. Drug release through ethylcellulose coated
dosage forms can be controlled by diffusion through the film coating. This can be a
slow process  unless  a  large  surface  area  (e.g.  pellets  or  granules  compared  with
tablets)  is  utilized.  In  those  instances,  aqueous  ethyl  cellulose  dispersions  are
generally  used  to  coat  granules  or  pellets.  Ethyl  cellulose  may  additionally  be
employed as a binder.
Various viscosity grades (mPa s) 
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Ethocel Std 4 Premium, Ethocel Std 7FP Premium, Ethocel Std 7 Premium
Ethocel  Std 10FP Premium, Ethocel  Std 10P  Premium, Ethocel  Std 14 Premium,
Ethocel Std 20P Premium, Ethocel Std 45P Premium, Ethocel  Med 50P Premium,
Ethocel Med 70P Premium, Ethocel Std 100FP Premium, Ethocel Std 100P Premium,
Ethocel Std 100P, Ethocel Std 200P Premium, Ethocel Std 300P Premium.
    8. Typical properties:-
• Density (bulk): 0.4 g/cm3
• Moisture content: Ethyl cellulose absorbs very little water from humid air or
during immersion, and that small amount evaporates easily.
• Glass transition temp:129-133°C
• Solubility: Practically insoluble in glycerine, propylene glycol and water 
• Viscosity: 7 to 100 cps for 5%w/v aqueous solution at 25°C
• Melting point: 240-255°C
9. Stability
Stable slightly hygroscopic material chemically resistant to alkali both dilute
and concentrated. Subject to oxidative degradation in the presence of sunlight or UV
light at elevated temperature.
 10. Incompatibility
             Incompatible with paraffin wax and microcrystalline wax.
  11. Safety
          Non toxic, non allergic and non irritating.
6.2.2 Povidone[84]
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1. Nonproprietary Names
      BP: Povidone
      JP: Povidone
      USP: Povidone
2. Synonyms
Kollidon, Plasdone, poly[1-(2-oxo-1-pyrrolidinyl)ethylene], polyvinylpyrrolidone,
PVP, 1-vinyl-2-pyrrolidinone polymer.        
3. Chemical Name and CAS Registry Number
      1-Ethenyl-2-pyrrolidinone homopolymer [900l3-39-8]
4. Empirical Formula and Molecular Weight
       (C6H9NO)n 2500–3 000 000
5. Structural Formula
                                               
6. Functional Category
Disintegrant, dissolution aid, suspending agent, tablet binder.
7. Applications in Pharmaceutical Formulation or Technology
 Although povidone is used in a variety of pharmaceutical formulations, it is
primarily used in solid-dosage forms. In  tableting,  povidone solutions are used as
binders in wetgranulation processes. Povidone is also added to powder blends in the
dry form and granulated  in situ  by the addition of water, alcohol, or hydroalcoholic
solutions. Povidone is used as a solubilizer in oral and parenteral formulations and has
been shown to enhance dissolution of poorly soluble drugs from solid-dosage forms.
Povidone solutions may also be used as coating agents. Povidone is additionally used
as a suspending, stabilizing, the solubility of a number of poorly soluble active drugs
may be increased by mixing with povidone.
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Use Concentration (%)
Carrier for drugs         10–25
Dispersing agent        Up to 5
Eye drops          2–10
Suspending agent        Up to 5
Tablet  binder,  tablet  diluent,  or
coating agent
         0.5–5
    
8. Description
Povidone occurs as a fine, white to creamy-white colored, odorless or almost
odorless, hygroscopic powder. Povidones with K-values equal to or lower than 30 are
manufactured by spray-drying and occur as spheres. Povidone K-90 and higher  K-
value povidone are manufactured by drum drying and occur as plates.
9 Typical Properties
           Acidity/alkalinity: pH = 3.0–7.0 (5% w/v aqueous solution).
           Melting point: softens at 150°C.
           Moisture content: povidone is  very hygroscopic,  significant  amounts of
moisture being absorbed at low relative humidities.
          Solubility: freely soluble  in  acids,  chloroform,  ethanol  (95%),  ketones,
methanol, and water; practically insoluble in ether, hydrocarbons, and mineral oil. In
water, the concentration of a solution is limited only by the viscosity of the resulting
solution, which is a function of the K-value.
           Viscosity (dynamic): the viscosity of aqueous povidone solutions depends on
both the concentration and the molecular weight of the polymer employed.
10. Stability and Storage Conditions
              It is stable to a short cycle of heat exposure around 110–130°C, it should be
stored in an airtight container in a cool and dry place.
11. Incompatibilities
           Povidone is compatible in solution with a wide range of inorganic salts,
natural  and synthetic  resins,  and other  chemicals.  It  forms  molecular  adducts  in
solution with sulfathiazole, sodiumsalicylate, salicylicacid, phenobarbital, tannins. 
6.2.3 Hydroxypropyl Cellulose, Low-substituted[84]
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1. Nonproprietary Names
        JP: Low-substituted hydroxypropylcellulose
        USPNF: Low-substituted hydroxypropyl cellulose
2. Synonyms
        Hyprolose, low-substituted, L-HPC.
3. Chemical Name and CAS Registry Number
       Cellulose, 2-hydroxypropyl ether (low-substituted) [78214-41-2]
4. Empirical Formula and Molecular Weight
        R is H or [CH2CH(CH3)O]mH
5. Structural Formula
         
6. Functional Categories
           Tablet and capsule disintegrant, tablet binder.
7. Applications in Pharmaceutical Formulation or Technology:
              Low-substituted hydroxypropyl cellulose is widely used in oral solid-dosage
forms.  It  is  primarily  used  in  tableting  as  a  disintegrant,  and  as  a  binder  in  wet
granulation.  In  addition,  low-substituted hydroxypropyl  cellulose has been used to
delay the release of drug from a tablet matrix. There are a number of grades that have
different  particle  sizes and substitution levels.  LH-11  has the medium substitution
level and the largest particle size, and is typically used as an anti capping agent and
disintegrant for direct compression.  LH- 21  is used as a binder and disintegrant for
tablets  through  the  wet-granulation  process.  LH-31  is  a  small-particle  grade  used
especially for extrusion to produce granules, as it has a small particle size that is better
for passing a screen. The typical content of low-substituted hydroxypropyl cellulose
in a formulation is approximately 5–25%.
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8. Description
            Low-substituted hydroxypropyl cellulose occurs as a white to yellowish white
powder or granules. It is odorless or has a slight, characteristic odor, and it is tasteless.
9. Typical Properties
           Acidity/alkalinity: pH = 5.0–7.5 for 1% w/v aqueous suspension.
           Melting point: decomposition at 275oC.
           Solubility: practically insoluble in ethanol (95%) and in ether, Dissolves in a
solution of sodium hydroxide (1 in 10) and produces a viscous solution. Insoluble, but
swells in water.
10. Stability and Storage Conditions
            Low-substituted hydroxypropyl cellulose is a stable, though hygroscopic,
material. The powder should be stored in a well closed container.
11. Incompatibilities
            Alkaline substances may interact. If  a tablet formulation contains such a
material, its disintegration may be extended after storage.
12. Safety
           Nontoxic and non irritant material.
6.2.4 Hydroxy propyl cellulose[84]
1. Nonproprietary Names
         BP: Hydroxypropylcellulose
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         JP: Hydroxypropylcellulose
         USPNF: Hydroxypropyl cellulose
2. Synonyms
         Cellulose, Hyprolose, Klucel, Methocel, Nisso HPC. 
3. Chemical Name and CAS Registry Number
         Cellulose, 2-hydroxypropyl ether [9004-64-2]
4. Empirical Formula and Molecular Weight
         Molecular weight has a range of 50 000–1 250 000; 
5. Structural Formula
         R is H or [CH2CH(CH3)O]mH
6. Functional Category
             Coating agent, emulsifying agent, stabilizing agent, suspending agent, tablet
binder, thickening agent, viscosity-increasing agent.
7. Applications in Pharmaceutical Formulation or Technology:
              Hydroxypropyl cellulose is widely used in oral and topical pharmaceutical
formulations; In oral products, hydroxypropyl cellulose is primarily used in tableting
as a binder, film-coating, and extended-release matrix former. The release rate of a
drug increases with decreasing viscosity of hydroxypropyl cellulose. The addition of
an anionic surfactant similarly increases the viscosity of hydroxypropyl cellulose and
hence decreases the release rate of a drug. A low-substituted hydroxypropyl cellulose
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is used as a tablet disintegrant, Hydroxypropyl cellulose is also used in cosmetics and
in food products as an emulsifier and stabilizer.
                  Use Concentration (%)
Extended release-matrix former          15–35
Tablet binder            2–6
Tablet film coating              5
8. Description
             Slightly yellow-colored, odorless and tasteless powder. 
9. Typical Properties
             Acidity/alkalinity: pH = 5.0–8.5 for a 1%w/v aqueous solution.
             Density (bulk): 0.5 g/cm3.
             Melting point: softens at 130°C; chars at 260–275°C.
             Moisture content:  Typical equilibrium moisture content values at 25°C are
4% w/w at 50% relative humidity and 12% w/w at 84% relative humidity.
             Solubility:  soluble 1 in 10 parts dichloromethane,1 in 2.5 parts ethanol
(95%),1 in 2 Parts methanol; 1 in 5 parts propan-2-ol,1 in 5 parts propylene glycol;
and  1  in  2  parts  water.  Practically  insoluble  in  aliphatic  hydrocarbons,  aromatic
hydrocarbons, carbon tetrachloride, petroleum distillates, glycerin, and oils.
            Viscosity (dynamic):  a wide range of viscosity types  are commercially
available.
10. Stability and Storage Conditions
            Hydroxypropyl  cellulose  powder  is  a  stable  material,  although  it  is
hygroscopic after drying. Aqueous solutions of hydroxypropyl cellulose are stable at
pH 6.0–8.0.
            Hydroxypropyl cellulose powder should be stored in a well closed container in
a cool and dry place.
11. Incompatibilities
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                Incompatibility with substituted phenol derivatives, such as methylparaben
and propylparaben. The presence of anionic polymers may increase the viscosity of
hydroxypropyl cellulose.
12. Safety
          Nontoxic and nonirritant material.
6.2.5 Sodium lauryl sulfate[84]
1. Nonproprietary Names
            BP: Sodium lauryl sulfate
            JP: Sodium lauryl sulfate
            USPNF: Sodium lauryl sulfate
2. Synonyms
           Dodecyl sodium sulfate, sodium dodecyl sulfate, sodium laurilsulfate, sodium
monododecyl sulfate.
3. Chemical Name and CAS Registry Number
           Sulfuric acid monododecyl ester sodium salt [151-21-3]
4. Empirical Formula and Molecular Weight
           C12H25NaO4S           Mol.wt :288.38
5. Structural Formula
 
6. Functional Category
            Anionic surfactant, detergent, emulsifying agent, skin penetrant, tablet and
capsule lubricant, wetting agent.
7. Applications in Pharmaceutical Formulation or Technology
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          Sodium lauryl sulfate is an anionic surfactant employed in a wide range of non
parenteral pharmaceutical formulations and cosmetics. It  is a detergent and wetting
agent effective in both alkaline and acidic conditions.
Use Concentration (%):0.5–2.5
8. Description
          Sodium lauryl sulfate consists of white or cream to pale yellow colored crystals,
flakes, or powder having a smooth feel, a soapy, bitter taste, and a faint odor of fatty
substances.
9. Typical Properties
            Acidity/alkalinity: pH = 7.0–9.5 (1% w/v aqueous solution)
            Density: 1.07 g/cm3 
            HLB value: 40
            Melting point: 204–207°C (for pure substance)
            Moisture content: 45%, sodium lauryl sulfate is not hygroscopic.
            Solubility: freely soluble in water, giving an opalescent solution, practically
insoluble in chloroform and ether.
10. Stability and Storage Conditions
Sodium lauryl  sulfate  is  stable  under  normal  storage  conditions.  The  bulk
material  should  be  stored  in  a  well-closed  container  away  from strong  oxidizing
agents in a cool, dry place.
11. Incompatibilities
 Sodium lauryl  sulfate  is  also  incompatible  with some alkaloidal  salts  and
precipitates with lead and potassium salts.
12. Safety
It is a moderately toxic material with acute toxic effects including irritation to
the skin, eyes, mucous membranes, upper respiratory tract and stomac.
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6.2.6 Talc[84]
1. Nonproprietary Names
       BP: Purified talc
       JP: Talc
       USP: Talc
2. Synonyms
        Altalc, Hydrous magnesium calcium silicate, Hydrous magnesium silicate.
3. Chemical Name and CAS Registry Number
        Talc [14807-96-6]
4. Empirical Formula and Molecular Weight
          Mg6 (Si2O5)4(OH)4. 
   
5. Functional Category
           Anti sticking agent, glidant, tablet and capsule diluent, tablet and capsule
lubricant.
6. Applications in Pharmaceutical Formulation or Technology
            Talc was once widely used in oral solid dosage formulations as a lubricant and
diluent. It is widely used as a dissolution retardant in the development of controlled-
release products. Talc is also used as a lubricant in tablet formulations and a novel
powder coating for extended-release pellets and as an adsorbent.
 Uses of talc:
 Use Concentration in percentage (%)
 Dusting powder: 90.0–99.0
 Glidant and tablet lubricant: 1.0–10.0
 Tablet and capsule diluent: 5.0–30.0
7. Description
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               Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous,
crystalline powder. It adheres readily to the skin and is soft to the touch and free from
grittiness.
8. Typical Properties
Acidity/alkalinity: pH = 7–10 for a 20% w/v aqueous dispersion.
Moisture content:  talc absorbs insignificant amounts of water at  25°C and relative
humidities up to about 90%.
Solubility:  practically  insoluble  in  dilute  acids  and  alkalis,  organic  solvents,  and
water.
Specific gravity: 2.7–2.8.
9. Stability and Storage Conditions
              Talc is a stable material and may be sterilized by heating at 160°C for not
less than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma
irradiation. Talc should be stored in a well-closed container in a cool, dry place.
10. Incompatibilities
              Incompatible with quaternary ammonium compounds.
11. Safety
              Inhalation of talc causes irritation and may cause severe respiratory distress.
6.2.7 Sugar Spheres[84]
1. Nonproprietary Names
         BP: Sugar spheres
         USPNF: Sugar spheres
2. Synonyms    
         Non-pareil, non-pareil seeds, sugar seeds, Suglets.
3. Functional Category
         Tablet and capsule diluent.
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4. Applications in Pharmaceutical Formulation or Technology
         Sugar spheres are mainly used as inert cores in capsule and tablet formulations,
particularly multi particulate sustained release formulations. They form the base upon
which a drug is  coated,  usually followed by a release-modifying polymer coating.
Alternatively,  a  drug  and  matrix  polymer  may  be  coated  onto  the  cores
simultaneously.  The  active  drug  is  released  over  an  extended  period  either  via
diffusion through the polymer or through to the controlled erosion of the polymer
coating.  Complex  drug  mixtures  contained  within  a  single-dosage  form  may  be
prepared by coating the drugs onto different batches of sugar spheres with different
protective polymer coatings.
5. Description
         Sugar spheres as approximately spherical granules of a labeled nominal-size
range with a uniform diameter and containing not less than 62.5% and not more than
91.5% of sucrose, calculated on the dried basis. The remainder is chiefly starch. The
diameter of sugar spheres varies from 200 to 2000 mm.
6. Typical properties
Density:  Particle size distribution:  sugar spheres  are of a uniform diameter.  30–35
mesh (500–600 mm)
Solubility:  solubility  in  water  varies  according  to  the  sucrose-to  starch  ratio.  The
sucrose  component  is  freely  soluble  in  water,  whereas  the  starch  component  is
practically insoluble in cold water.
7. Stability and Storage Conditions
            Sugar spheres are stable when stored in a well-closed container in a cool, dry
place
6.2.8 Isopropyl alcohol[84]
1. Nonproprietary Names
        BP: Isopropyl alcohol
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        JP: Isopropanol
        USP: Isopropyl alcohol
2. Synonyms
               Dimethyl carbinol; IPA; isopropanol;2-propanol;sec-propyl alcohol.
3. Chemical Name and CAS Registry Number
               Propan-2-ol [67-63-0]
4. Empirical Formula and Molecular Weight
               C3H8O      Mol.wt: 60.1
5. Structural Formula
                                        
6. Functional Category
            Disinfectant, solvent.
7. Applications in Pharmaceutical Formulation or Technology
Isopropyl  alcohol  (propan-2-ol)  is  used  in  cosmetics  and  pharmaceutical
formulations primarily as a solvent in topical formulations. It is not recommended for
oral use owing to its toxicity Isopropyl alcohol is also used as a solvent both for tablet
film-coating and for  tablet  granulation, therapeutically,  isopropyl  alcohol  has been
investigated for the treatment of postoperative nausea or vomiting.
8. Description
Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid with
a characteristic, spirituous odor resembling that of a mixture of ethanol and acetone; it
has a slightly bitter taste.
9. Typical Properties
      Boiling point: 82.48C
      Flammability: flammable.
      Melting point: 88.58C
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      Moisture content: 0.1–13% w/w.
      Solubility: miscible with benzene, chloroform, ethanol (95%),ether, glycerin, and
water. Soluble in acetone, insoluble in salt solutions. 
10. Stability and Storage Conditions
Isopropyl alcohol should be stored in an airtight container in a cool, dry place.
11. Incompatibilities
Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid,
which cause decomposition. 
.
12. Safety
Isopropyl  alcohol  is  widely  used  in  cosmetics  and  topical  pharmaceutical
formulations. 
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7. EXPERIMENTAL INVESTIGATION
7.1 Preparation of standard curve of Indomethacin[85]:
The  drug  in  solution  with  concentration  of  50  µg/ml  was  prepared.  Serial
dilutions  of  5-50 µg/ml  drug concentration were made by using the methanol  and
phosphate buffer pH 6.2. They were analyzed spectrophotometrically by measuring
the absorbance at 319 nm wavelength.
 (a) Preparation of pH 6.2 phosphate buffer [86]:
Potassium dihydrogen orthophosphate (KH2PO4) 68 gms was taken in 10 liters
of purified water and 3.24 gms of sodium hydroxide pellets was mixed and adjusted to
pH 6.2.
(b) Calibration curve of Indomethacin in 6.2 pH phosphate buffer:
Drug (100 mg) was dissolved in 100 ml of methanol from this solution 5 ml
was withdrawn and diluted to 100 ml with phosphate buffer pH 6.2. From the stock
solution serial  dilution were made to  obtain the solution in concentrations  ranging
from  5-50  µg/ml.  They  were  analyzed  spectrophotometrically  by  measuring  the
absorbance at 319 nm.
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Table No: 3 Standard calibration curve of Indomethacin at pH 6.2
               
S. No
Concentration
(µg/ml) Absorbance
1 5 0.092
2 10 0.196
3 15 0.295
4 20 0.393
5 25 0.492
6 30 0.597
7 35 0.688
8 40 0.784
9 45 0.885
10 50 0.983
Figure No: 11 Standard calibration curve of Indomethacin
7.2 Preformulation studies [87]:
Preformulation  testing  is  defined  as  investigation  of  physical  and  chemical
properties of drug substances alone and when combined with excipients.          
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7.2.1 Spectroscopic studies [87, 88]:
               1. UV Spectroscopic Analysis
               2. IR Spectroscopic Analysis
(a) UV spectroscopy (Determination of λ max)
                The light absorption in the range 200 to 800 nm of a solution buffer it
exhibit a maximum only at about 319 nm.
(b) Raw material analysis of Indomethacin USP [86]:
               Raw material analysis of Indomethacin was carried out using Fourier
Transform Infra red spectrophotometer (FTIR) by KBr pellet method.
7.2.2 Particle size distribution of Indomethacin powders [67]:
           The particle size measurement of indomethacin micronized powder was
determined  by  using  a  (Mastersizer-2000)  particle  size  analyzer.  An  appropriate
amount of indomethacin powder was added into the analyzing chamber containing
deionized water as the medium. A few drops of Triton solution (1% w/w) were added
to disperse the powders. Test results of the type of powder were recorded. In addition,
this powder was examined under a microscope with a magnification of 400X. 
7.2.3 Compatibility studies of Indomethacin and formulation components:
              The compatibility of drug and polymers under experimental conditions is
important prerequisite before formulation. It is therefore necessary to confirm that the
drug does not react with the polymers and excipients under experimental conditions
and  not  affecting  the  shelf  life  of  product  or  any  other  unwanted  effects  on  the
formulation. The physical mixture of drug & polymers were used for determination of
Infrared spectrums. 
7.2.4 Physical observation [54, 79]:
             The active ingredients were mixed well with all excipients in binary ratio and
small portion of this mixed powder was placed in cleaned and dried vial in stability
chamber at 25°C/ 60% RH & 40°C/ 75% RH. Physical observation has been carried
out visually for 0, 2 and 4 weeks.
7.3 Formulation development:
                  Study involves formulation of an extended release Indomethacin drug
loaded pellets, release over an extended period of time.
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Selection of Process
     Pellets were done by Fluid bed processor (FBP).
     General procedure for formulation of extended release pellets:
     Preparation of drug layering solution:
• Required quantity of isopropyl alcohol was taken into a suitable vessel and to it
ethyl cellulose 4cps added and stirred well to get clear solution. This process
was done at room temperature. 
• To  the  above  solution  purified  water,  sodium  lauryl  sulfate  and  hydroxy
propylcellulose  were  added  slowly  under  continuous  stirring  to  dissolve
completely. 
• Then  Indomethacin  was  added  slowly  under  continuous  stirring  to  get  a
uniform  dispersion.  After  attaining  uniform  dispersion  talc  was  added
immediately with continuous stirring for not less than 30 min.
• The above dispersion was passed through #40 sieve and complete dispersion
was passed.
• Dispensed  sugar  spheres  were  loaded  into  wurster  column and  the  process
started with present parameters to adjust the fluidization.
• The dispersion was sprayed onto sugar spheres at inlet temperature of 40±5°C
and bed temperature of 35 ±5°C then spray rate increased slowly to optimum
rate.
• The  drug  layered  pellets  was  dried  for  not  less  than  15  min  with  low
fludization at a bed temperature of 40±5°C and weight gain was checked.
• The drug layered pellets were passed initially through #20 sieve and the twins
retained on the sieve were removed. Again they are passed through #30 sieve
and the passed drug layered pellets were discarded.
• The pellets were stored in suitable air tight container.
Extended release coating:
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• Extended release coating solution in which polymer concentration 1:1 ratio
was prepared (5%, 7% and 9%) weight build up was noted.
• Required quantity of isopropyl alcohol was transferred into a suitable vessel at
room temperature to that ethyl cellulose 4 cps, purified water, hydroxypropyl
cellulose  was  added  slowly  under  continuous  stirring  until  it  dissolves
completely.
• The drug layered  pellets  were loaded into wurster  column and the process
started with present parameters to adjust the fluidization.
• The solution was sprayed  onto drug layered  pellets at  inlet  temperature  of
40±5°C and bed temperature of 35±5°C then spray rate increased slowly to
optimum rate.
• The extended release coated pellets was dried for not less than 30 min with
low fluidization at  a  bed temperature  of  40±5°C and weight  build  up was
checked
• The extended release coated pellets were passed initially through #20 sieve
and the  twins  retained  on the  sieve  were  removed.  Again  they are  passed
through #30 sieve and the passed drug layered pellets were discarded.
Lubrication
• The talc was passed through #40 sieve and pellets were lubricated.
7.3.1 Parameters in capsule:
Table No: 4
Capsule shells Green  opaque  cap/clear  transparent  body  size  1  empty
hard gelatin capsule shell imprinted with X08 on both cap
and body with black ink.
Description   Green  opaque  cap/clear  transparent  body  size  1  hard
gelatin  capsule  shells  filled  with pale  yellow pellets  &
imprinted with X08 on both cap and body with black ink.
7.3.2 Parameters maintained in fluid bed processor:
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Table No: 5
Machine type Pam Glatt 1.1 
Material nozzle diameter 0.8 mm
Number of guns 01
Spray mode Continuous 
Inlet air temperature 50±10°C
Product temperature 40±5°C
Exhaust temperature 40±5°C
Atomization 2-3 bar
Air flow 600 -750 m/sec
Drive speed 55-65%
Peristaltic pump  speed 08-12 rpm
Table:6: 7.3.3 Formulation chart of Indomethacin pellets:
   Drug layering
S.
No
Ingredients
Quantity per unit (mg)
F-1 F-2 F-3 F-4 F-5 F-6
1 Indomethacin 75 75 75 75 75 75
2 Ethyl cellulose (4cps) 5 5 5 7 5 5
3 Povidone K30 20 - - - - -
4 Hydroxypropyl Cellulose, 
Low-substituted
- 20 - - - -
5 Hydroxypropyl Cellulose - - 20 18 20 20
6 Sodium lauryl sulfate 0.5 0.5 0.5 0.5 0.5 0.5
7 Talc 1 1 1 1 1 1
8 Sugar spheres (500-600 µm) 217.5 217.5 217.5 217.5 217.5 217.5
9 Isopropyl alcohol q.s q.s q.s q.s q.s q.s
10 Purified water q.s q.s q.s q.s q.s q.s
 Extended release coating
S. No Ingredients
Quantity per unit (mg)
F-1 F-2 F-3 F-4 F-5 F-6
     11 Ethyl cellulose 
(4cps)
8 8 8 8 11 14
12 Povidone K30 8 - - - - -
13 Hydroxypropyl - 8 - - - -
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Cellulose, Low-
substituted
14 Hydroxypropyl 
Cellulose
- - 8 8 11 14
15 Sodium lauryl 
sulfate
1 1 1 1 1 1
16 Isopropyl alcohol
q.s q.s q.s q.s q.s q.s
17 Purified water q.s q.s q.s q.s q.s q.s
Extended release 
pellet weight
336 336 336 336 342 348
18 Talc 1 1 1 1 1 1
7.4 Evaluation of prepared pellets: [89]
7.4.1 (i) Bulk density:
Weighed quantity of 60 gms pellets was transferred into a 100 ml measuring
cylinder  without  tapping,  during  transfer  the  volume  occupied  by  pellets  was
measured. Bulk density was measured by using formula.
                                                          Pi = m/Vo  
   Where,
             Pi = Bulk density
             m = Mass of the pellets, 
             Vo = Untapped Volume
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7.4.1 (ii) Tapped Density:
Weighed quantity of 60 gms pellets was taken into graduated cylinder, volume
occupied by granules was noted down. Then cylinder was subjected to 500 taps in
tapped density tester (Electro Lab USP II), the % Volume variation was calculated by
following formula.
                                          Pt = m/Vi
Where,
            Pt = Tapped density
            m= Mass of the pellets, 
            Vi = Tapped volume
7.4.2 Carr’s compressibility index:
Compressibility is the ability of pellets to decrease in volume under pressure.
Using untapped density and tapped density the percentage compressibility of pellets
were determined, which is given as Carr’s compressibility index.
                                           
                               CI=Vi-Vo / Vi × 100
Where, 
 CI   = Compressibility index            
 Vo  = Bulk density 
 Vi
 
  = Tapped density   
                              
Table No: 7 Compressibility index
 
7.4.3 Hausner´s ratio
It is measurement of frictional resistance of the drug. It was determined by the
ratio of tapped density and bulk density.
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Compressibility index (%) Flow characters
<   10 Excellent
11-15 Good
16-20 Fair
21-25 Passable
26-31 Poor
> 32 Very poor
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    Hausner´s ratio = Vo/Vi
Where, 
             Vo = Bulk density 
 Vi  = Tapped density 
Table No: 8 Hausner´s ratio
             
7.4.4 Procedure for content uniformity: [86]
             The content of one capsule was transferred into 200 ml volumetric flask, to it
100 ml equal volume of methanol and phosphate buffer (pH 6.2) was added. Then the
solution was sonicated until then contents are dispersed and volume was made up
with methanol and phosphate buffer  (pH 6.2)  in  1:1 ratio.  This solution contains
about 25 µg/ml  indomethacin.  Concomitantly the absorbance was determined 319
nm, in spectrophotometer, using the methanol and pH 6.2 phosphate buffer mixture
as the blank.
       By calculating the formula: 
                                                (TC/D)(AU/AS)
T = labeled quantity of indomethacin in mg
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Flow characters Hausner´s  ratio
Excellent 1.11
Good 1.12 – 1.18
Fair 1.19 – 1.25
Passable 1.26 – 1.34
Poor 1.35 – 1.45
Very poor 1.46 – 1.59
Very very poor >1.60
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C= concentration (µg per ml) in the standard solution
D= concentration (µg per ml) in the test solution
Based upon the labeled quantity per capsule and the extent of dilution
Au and As are the absorbance of the solution from the capsule contents and the
standard solution.
7.4.5 Capsule weight variation [55, 57]
        Individual weights of 20 capsules were taken and the average weight was
calculated by using the following formula.
                                              (Capsule weight -Average weight)   
         Weight variation =     -----------------------------------------------  × 100
                                                  Average weight of capsules
Weight variation should not be more than 7.5 %
7.4.6 Percentage yield [55, 79]
              The yield was determined by weighing the pellets and then finding out the
percentage yield with respect to the weight of the input materials.
                The formula for calculation of percentage yield is
                                                                Weight of pellets
           Percentage yield (%)    =  ---------------------------------------- × 100
                                                     Weight of drug + Weight of polymers
7.4.7 Lock length [54, 79]
After  filling the capsules  to determined lock length in these ten individual
capsules were taken from each formulation trial batch and lock length was measured
manually by using vernier calipers and average of ten capsules was noted.
7.4.8 Loss on drying: 
It  was  done  in  Electronic  Loss  on  Drying  (LOD)  apparatus  (Sartorius,
Germany).  Weighed  quantity  of  1  gm  sample  was  placed  in  the  pan  and  the
temperature was increased to 105oC and the loss on drying in % was noted.
7.4.9 IN-VITRO DRUG RELEASE STUDIES [86]: 
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In-vitro drug release studies of indomethacin were carried by using apparatus
USP test-Ι rotation basket method with a stirring speed 75 rpm at 37 ± 0.5°C in 750ml
of 6.2 phosphate buffer for 24 hours. 5 ml of sample, with drawn at interval of 1, 2, 4,
6, 12, 24 hours with the replacement of equal volume of dissolution media.
Filtered  the  solution  through  millipore  HYLP  filter  and  these  filtrate  was
measured at 319 nm by UV spectrophotometer (UV-1700 SHIMADZU)
The percentages of the labeled amount of indomethacin dissolved at the time
specified acceptance table.
                                                    Table No: 9
Time (hours) Amount dissolved
1 Between 10% and 25%
2 Between 20% and 40%
4 Between 35% and 55%
6 Between 45% and 65%
12 Between 60% and 80%
24 Not less then 80%
7.4.10 Comparison of Dissolution Profile with Marketed Product
The dissolution profile (in USP 6.2 phosphate buffer)  of optimized formula
was compared with the dissolution profile of marketed product and the results were
noted.
7.5 Kinetics of drug Release [90, 91]:
To analyze the mechanism of release and release rate kinetics of the dosage
form, the data obtained were fitted into Zero order, First order, Higuchi and Peppas.
Based on the R & n value, the best-fit model was selected.
1.  Zero order kinetics:
Zero order release would be predicted by the following equation
At = A0 – K0t
Where,
At  =  Drug release at time ‘t’.
A0  = Initial drug concentration
K0t  = Zero – order rate constant (hr-1).
When the data is plotted as cumulative percent drug release versus time, if the
plot is linear then the data obeys Zero-order release kinetics, with a slope equal to K0.
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2.  First Order Kinetics:
First – order release would be predicted by the following equation
Log C = log C0 – Kt / 2.303
Where,
C = Amount of drug remained at time‘t’.
C0 = Initial amount of drug.
            Kt = First – order rate constant (hr-1).
When the data is plotted as log cumulative percent drug remaining versus time
yields  a  straight  line,  indicating  that  the  release  follow first  order  kinetics.   The
constant ‘K’ can be obtained by multiplying 2.303 with the slope values.
3.  Higuchi’s model:
Drug  release  from  the  matrix  devices  by  diffusion  has  been  described  by
following Higuchi’s classical diffusion equation.
Q = [Dε / τ (2 A - εCs) Cst]1/2
Where,
Q    = Amount of drug released at time‘t’.
            D    = Diffusion coefficient of the drug in the matrix.
            A    = Total amount of drug in unit volume of matrix.
Cs   = Solubility of the drug in the matrix.
ε  = Porosity of the matrix.
τ = Tortuosity.
 t     = Time (hrs) at which ‘q’ amount of drug is released.
Above equation may be simplified if one assumes that ‘D’, ‘Cs’, and ‘A’, are
constant.  Then equation becomes:
                                                   Q = Kt1/2 
When the data is plotted according to equation i.e. cumulative drug release
versus square root of time yields a straight line, indicating that the drug was released
by diffusion mechanism.  The slope is equal to ‘K’.
4.  Korsmeyer equation / Peppa’s model:
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To study  the  mechanism of  drug  release,  it  was  further  plotted  in  peppas
equation as log cumulative % of drug released Vs time.
 
Mt / Ma = Ktn
Where,
Mt / Ma = the fraction of drug released at time ‘t’.
         K = Constant incorporating the structural and geometrical characteristics
of the drug / polymer system.
          n = Diffusion exponent related to the mechanism of the release.
Above equation can be simplified by applying log on both sides
                                                Log Mt / Ma  =  Log K + n Log t
When the data is plotted as log of drug released Vs log time, yields a straight line with
a slope equal to ‘n’ and the ‘K’ can be obtained from y – intercept and range was
shown in the table no.10
Mechanism of Drug release as per Korsmeyer Equation / Peppa’s Model
Table No.10
S. No. N Value Drug release
                 1 0.45 Fickian release
                 2 0.45 <n <0.89 Non – Fickian release
                 3 n> 0.89 Class II transport
7.6 Stability studies [59]:
In  any rationale design and evaluation of dosage forms, the stability of the
active component must be major criteria in determining their acceptance or rejection.
Reasons for stability studies:
• There  may  be  chemical  degradation  of  the  active  drug  leading  to  a
substantial  lowering  the  quantity  of  the  therapeutic  agent  in  the  dosage
form.
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• Although chemical degradation of the active drug may not be extensive, a
toxic product may be formed in the decomposition process.
• Instability of a drug product can lead to a decrease in its bioavailability.
This can lead to a substantial lowering in the therapeutic efficiency of the
dosage form.
The drug release profile of batch F5 met the dissolution acceptance criteria to
pass the amount of drug release test according to USP requirements. In this batch F5
was selected as optimized batches  and subjected to further  studies.  The optimized
batch F5 was charged for stability at 40°C/ 75% RH for 2 months. The drug release
studies were repeated after storage for 2 months at conditions like room temperature
(RT) and 40°C/ 75% RH.
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8. RESULTS AND DISCUSSION
8.1 Drug- Excipient compatibility study: 
            Drug-Excipients compatibility study was carried out using various Excipients
mentioned below table no.11. From the preformulation studies, it was observed that
mixtures shown have no color change.  
Table No: 11 Physical observation
S. No Composition details
Initial Physical
Description
25°C /60 % RH
&
40°C/ 75 % RH
1st Week 2nd Week 3rd Week
1 Indomethacin   Light yellowish 
        Powder   
NCC NCC NCC
2 Indomethacin + 
Hydroxy propyl 
cellulose  
White to light 
yellowish powder NCC NCC NCC
3 Indomethacin + 
povidone K30
White to light 
yellowish powder
NCC NCC NCC
4 Indomethacin + low 
substitued hydroxy 
propyl cellulose
White to light 
yellowish powder NCC NCC NCC
5 Indomethacin + Ethyl
cellulose (4cps) 
White to light 
yellowish powder
NCC NCC NCC
6 Indomethacin + 
sodium lauryl sulfate
Light yellowish  
powder
NCC NCC NCC
7 Indomethacin + Talc Light yellowish  
powder
NCC NCC NCC
8 Indomethacin + sugar
spheres
White to light 
yellowish powder
NCC
NCC NCC
NCC: NO COLOUR CHANGE
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8.2. Spectroscopic studies:
8.2.1 UV spectroscopy (Determination of λmax)
• The observed λmax was 319.60 nm.
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8.2.2 IR Spectra of drug
  
   Interpretation of Indomethacin
Frequency Groups Assigned
3452.3 O-H Stretching
3022.0 C-H Stretching
1692.0 C=O Stretching
1455.2 C=C Stretching
925.8 C-H  Bending
8.2.3 IR Spectrum of optimized formulation F-5
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Interpretation F-5
Frequency Groups Assigned
3676.2 O-H Stretching
3022.0 C-H Stretching
1613.8 C=O Stretching
1455.4 C=C Stretching
925.8 C-H  Bending
Discussion:
When  FT-IR  Spectrum  of  indomethacin  (pure  drug)  and  optimized
formulation of Indomethacin extended release pellets (F5) were compared, there were
no major changes in the position of the spectrum. So it indicates absence of physical
and chemical interactions of Indomethacin extended release pellets. 
8.3 Indomethacin particle size range 
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Figure No.12
Magnification of 400X
Indomethacin micronized powder
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8.4 Evaluation of pellets of Indomethacin
 
Table No: 12
8.4.1 Bulk Density & Tap Density
Both bulk density and tapped bulk density results are shown in table no.12.
The  bulk  density  and  tapped  bulk  density  for  all  formulation  varied  in  range  of
0.821±0.011 to 0.873±0.014 and 0.873±0.019 to 0.918±0.008. The value obtained lies
within the acceptable range and with no much difference found between bulk density
and tapped bulk density. These results may further influence the pellets dissolution.
8.4.2 Compressibility Index & Hausner’s Ratio
The  percent  compressibility  of  pellets  was  determined  by  Carr’s
compressibility  index  as  shown  in  table  no.12.The  percent  compressibility  for  all
formulation lies within the range  of 6.01±1.57 to 6.209±0.63. Hausner’s ratio  was
found  to  be  in  a  range  of  1.036±0.017  to  1.074±0.017  which  shows  good  flow
property.
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S. No
Bulk density
(g/cc)
Tap density
(g/cc)
Carr’s Index
(%)
Hausner´s
ratio
      F-1 0.837±0.006 0.890±0.007 6.01±1.57 1.074±0.017
      F-2 0.833±0.012 0.886±0.015 6.012±0.79 1.06±0.008
      F-3 0.821±0.011 0.873±0.019 5.978±0.82 1.06±0.009
      F-4 0.837±0.013 0.886±0.015 5.698±0.25 1.058±0.0005
      F-5 0.845±0.012 0.899±0.008 6.209±0.63 1.049±0.030
      F-6 0.873±0.014 0.918±0.008 4.866±0.73 1.036±0.017
                                                                Results & Discussion
8.4.3 Content uniformity:
The results  for  uniformity of  dosage  units  are  presented  in  the  table given
below. The results were found to be within the limits (90 % to 110%). It shows that
the drug was uniformly distributed.
Table No: 13
               
               
 *Average
values  of the  three
8.4.4 Yield & capsule lock length:
The  results  for  yield  observed  NLT  96%  and  capsule  lock  length  were
presented in the table given below. 
                                                               Table No: 14          
  Formulation
      batches 
   Percentage
     yield (%)
   Capsule lock 
  Length in(mm)
F1 99.36      19.30±0.10
F2 98.81 19.33±0.09
F3 99.47 19.35±0.10
F4 98.3 19.31±0.09
F5 98.71 19.33±0.11
F6 97.84 19.32±0.09
8.4.5 Weight variation & Loss on drying
The weight of the capsule was fixed depending up the percentage of excipients
used in the each formulation .Weight variation of the prepared capsules was within the
limit .Mostly, the variation was within ± 7.5%. 
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S. No
Drug layered
pellets of Content
uniformity in (%)
Extended layered
pellets of Content
uniformity in (%)
      F-1       100.5 ± 0.75       99.1 ± 0.73
      F-2       100.9 ± 0.66       99.4 ± 0.95
      F-3       100.2 ± 0.37       99.0 ± 0.66
      F-4       100.2 ± 0.45       98.3 ± 1.05
      F-5       100.7 ± 1.19       99.1 ± 0.36
      F-6        99.8 ± 0.16        98 ± 0.65
                                                                Results & Discussion
The  prepared  pellets  of  all  the  batches  were  evaluated  for  their  moisture
content. It is observed that the range around 1%.
                                                    Table No: 15
*Average values of the three determinations are given as results
8.4.6 Extended release formulation of Indomethacin pellets
The  in-vitro release studies of F1-F6 formulations were carried out by UV
method and reported.  The limits for indomethacin Extended release capsule as per
USP are listed in the table
USP limits for drug release for indomethacin extended release capsules   
                                                          Table No: 16
Time (hours)        Amount dissolved
1 Between 10% and 25%
2 Between 20% and 40%
4 Between 35% and 55%
6 Between 45% and 65%
12 Between 60% and 80%
24 Not less then 80%
Table No: 17. In-vitro dissolution data of F1                
S. No
Time
(hrs)
Amount of drug
Release
% drug release
Cumulative %
drug release
1 1 29.08 38.77 38.77
2 2 39.13 52.17 52.42
3 4 48.12 64.16 64.50
4 6 54.21 72.28 72.71
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S. No Weight(mg)± SD Loss on drying(%)
F-1 409 ± 1.89 1.22 ± 0.02
F-2 409 ± 2.63 1.20 ± 0.03
F-3 409 ± 2.78 1.17 ± 0.02
F-4 409 ± 2.52 1.18 ± 0.02
F-5 415 ± 2.02 1.21 ± 0.02
F-6 421 ± 1.73 1.18 ± 0.01
                                                                Results & Discussion
5 12 67.45 89.94 90.42
6 24 73.81 98.41 99.01
Figure No: 13. In-vitro dissolution data of F1
Table No: 18.  In-vitro dissolution data of F2
S. No Time  (hrs)
Amount of
drug
Release
% drug
release
Cumulative %
drug release
   1        1        27.25 36.33 36.33
   2        2        35.46 47.28 47.52
   3        4        45.37 60.49 60.80
   4        6        53.90 71.86 72.26
   5       12        61.52 82.02 82.50
   6       24        72.78 97.04 97.59
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Figure No: 14. In-vitro dissolution data of F2
Table No: 19 In-vitro dissolution data of F3
                 
S. No Time  (hrs) Amount of drug
Release
% drug
release
Cumulative %
drug release
1        1          21.62 28.83 28.83
2        2          30.76 41.01 41.20
3        4          42.10 56.13 56.40
4        6          50.55 67.40 67.77
5       12          59.54 79.38 79.83
6       24          72.93 97.24 97.77
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Figure No: 15 In-vitro dissolution data of F3
Table No: 20 In-vitro dissolution data of F4
                  
S.
No
Time (hrs) Amount of drug
release
% drug
release
Cumulative %
drug release
1 1 20.55 27.40 27.41
2 2 31.59 42.12 42.31
3 4 44.40 59.20 59.49
4 6 47.66 63.54 63.94
5 12 56.49 75.32 75.74
6 24 72.24 96.32 96.82
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Figure No: 16 In-vitro dissolution data of F4
Table No: 21 In-vitro dissolution data of F5
                  
S.
No
Time  (hrs) Amount of drug
release
% drug
release
Cumulative %
drug release
1 1 12.99 17.32 17.32
2 2 23.50 31.33 31.44
3 4 30.56 40.74 40.94
4 6 39.95 53.26 53.53
5 12 51.03 68.04 68.39
6 24 72.63 96.84 97.29
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Figure No. 17 In-vitro dissolution data of F5
Table No: 22 In-vitro dissolution data of F6
                  
S. No Time  (hrs)
Amount of drug
release
% drug
release
Cumulative %
drug release
1 1 5.47 7.30 7.30
2 2 18.14 24.19 24.23
3 4 26.56 35.42 35.58
4 6 34.51 46.02 46.25
5 12 47.79 63.72 64.02
6 24 67.44 89.93 90.35
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Figure No: 18. In-vitro dissolution data of F6
 In the sugar spheres size (#30/35) was selected in the formulation used with
ethyl cellulose (release retarding agent) and povidone K30 (binder), low substituted
hydroxypropyl  cellulose  (binder),  hydroxypropyl  cellulose  (binder),  sodium lauryl
sulfate (anionic surfactant), talc (lubricant) used in the extended release coating.
In the formulation (F-1) the sugar sphere size (#30/35) are coated with drug
layering  containing  ethyl  cellulose(4cps)  and  povidone K30 and  extended  release
(5%) coating buildup containing ethyl cellulose(4cps) and povidone K30 (1:1) ratio.
Then the dissolution parameters are observed that they were not close to the U.S.P
dissolution limits. This may be due to less binding capacity the polymer.
So in the formulation (F-2) the ethyl cellulose (4cps) was kept constant and
binder (povidone K30) is substituted with low substituted hydroxy propyl cellulose
and the dissolution parameters are checked. In  these formulation better results was
observed when compared with (F-1) and they were close to the dissolution limits. But
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they did not exactly match with the dissolution limits of USP. This also may be due to
improper binding of the polymer used.
In  the  formulation  (F-3)  the  low  substituted   hydroxy  propyl  cellulose
substituted with hydroxyl propyl cellulose and here also ethyl cellulose (4cps) was
kept constant  and the dissolution parameters are checked then the results are very
close to the U.S.P dissolution limits than F-1 and F-2.
From  that  to  obtain  better  results  in  the  dissolution  (F-3)  consider  to
formulation F-4 to change in the concentration of ethyl  cellulose, hydroxyl  propyl
cellulose in the drug layered pellets and extended release coating is kept constant.
Hence a very little change was observed in the dissolution timing (6th, 12th, 24th) hours.
Based  on  formulation  (F-3)  to  formulate  a  further  formulation  (F-5)  to
concentration of ethyl cellulose (4cps) and hydroxypropyl cellulose was increased in
extended release coating (7%) buildup in 1:1 ratio. Then the dissolution profile was
checked these results were exactly matched with the U.S.P limits.
In the next formulation (F-6) the polymer concentration was increased than F-
5. Here when the dissolution parameters were checked the 1st hour release did not
satisfy the USP limits. The further results at different interval have passed the USP
dissolution limits.
From  the  results  obtained  from  the  above  formulations  it  shows  that  the
formulation F-5 is the best formulation among the all.
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Figure No: 19. Optimized formulation (F-5) Indomethacin pellets
Figure No: 20. Optimized formulation (F-5) Indomethacin capsule
8.5 Comparison of dissolution Profile with marketed product 
  In which formulation (F-5) evaluation indicated that the dissolution profile of
optimized formulation was comparable to the dissolution profile of marketed sample.
It shows better release compared to market product.  
Dissolution  Data  of  Market  Sample  Vs  Optimized  Formulation  (F5)  in  6.2
phosphate buffer  
Table No: 23
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Time in
hours
Ref(SANDOZ)
Optimized
formulation-F5
Cumulative % of
drug release
Cumulative % of
drug release
1 11.41 18.21
2 24.32 32.37
4 45.67 41.84
6 52.02 52.13
12 60.81 67.49
24 78.47 97.21
                                                                   
Figure No: 21
8.6 Kinetic Studies:
(i) Zero order kinetic plot 
Figure No: 22
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                                                              Table No: 24
Zero order
R2
0.9796
(ii) First order kinetic plot
                                     
Figure No: 23
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                                                               Table No: 25 
First order kinetics
R2
0.9187
(iii) Higuchi plot 
                 
Figure No: 24
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                                                             Table No: 26
 
Higuchi Plot
R2
0.9958
(iv) Korsmeyer-Peppas plot
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Figure No: 25
                          
                                                             Table No: 27
Release Kinetics study for optimized extended release pellets:
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                    Korsemeyer-Peppas plot
                                        N
0.454
                                                                Results & Discussion
The tables and figures showed the correlation coefficient of different kinetic
model for optimized (F-5) formulation. Higuchi plots were found to be of highest
linearity with correlation coefficient greater than that of the zero order kinetics and
correspond  to  that  of  the  first  order  kinetics  indicating  that  the  drug  release
mechanism from these pellets by diffusion method. Studies revealed that release was
found to be very close to zero- order kinetics with a value of 0.9796 indicating that
the release was nearly independent of drug concentration. The  in-vitro release was
explained  by higuchi  model  with  a  value  of  0.9958 indicates  a  diffusion  release.
Moreover  in-vitro release explained by korsmeyer-peppas equation also indicated a
good  linearity.  The  release  exponent  "n"  was  0.454,  which  indicates  the  fickian
diffusion model.
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8.7 COMPARATIVE IN –VITRO DRUG RELEASE PROFILE BEFORE AND
AFTER  1  MONTH  AND 2 MONTH STORAGE  AT(40°C / 75% RH.) OF
BATCH F5
                                                             Table No: 28
Time in
hours
INITIAL 1 MONTH 2 MONTH
Amount of
drug
release
Cumulative
(%)
drug  release
Amount of
drug
release
Cumulative
(%)
drug  release
Amount of
drug
release
Cumulative
(%)
drug  release
1 12.99 17.32 12.72 16.96 14.05 18.74
2 23.50 31.45 24.03 32.15 24.85 33.26
4 30.56 40.95 30.94 41.47 30.94 41.48
6 39.95 53.54 40.73 54.58 38.91 52.16
12 51.03 68.39 49.68 66.60 53.42 71.57
24 72.63 97.03 72.63 97.28 73.84 98.93
                                                     
Figure No: 26
  8.7.1 DRUG CONTENT
                                                     Table No: 29
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Time (month) 40°C / 75 % RH
Initial 98.4 ± 1.09
1st month 97.5 ± 1.05
2nd month 97.03 ± 0.98
*Average values of the three determinations are given as results
STABILITY STUDIES
It is observed that no variation occurs in case of dissolution profile and drug
content when it is stored in 40°C / 75% RH stability chamber.
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CONCLUSION  
9. CONCLUSION
The  present  work  was  carried  out  to  design  and  evaluate  Indomethacin
capsules containing extended release pellets. Indomethacin is a NSAID and is one of
the most widely used drug for treating mild and severe pains.    
The combination of ethyl cellulose and other polymers the drug release rate
increased due to a formation of a porous on the pellets.
Formulation  F-5  (containing  ethyl  cellulose  5%  w/w  and  hydroxypropyl
cellulose 9%w/w) showed better release profile i.e. very low initial drug release in the
first two hrs and afterwards the rate of drug release increased with almost complete
release of the drug being achieved in 97.03% at 24 hrs respectively. Hence F-5 release
profile was passed all USP test-1 limits and further continuous for kinetic study and
stability studies.
Pellets  technique  using  ethyl  cellulose  as  the  retardant  has  successfully
extended the release of indomethacin from its pellets formulations.
            In  the present study,  it  was found that  incorporation of hydroxypropyl
cellulose  in  the  pellets  not  only helped  to  provide  good  initial  retardation  in  the
release but also helps to enhance the overall release rate of the drug after a suitable lag
time and also it will act as suitable binding property.
The result of formulation (F-5) evaluation indicated that the dissolution profile
of  optimized  formulation  was  comparable  to  the  dissolution  profile  of  marketed
sample. It shows better release compared to market product.  
Optimized  formulation  F-5  was  subjected  to  data  obtained  from  stability
studies indicate that there is no much change in the release profile and drug content of
pellets. Hence the prepared pellets of formulation (F-5) were found to be stable.
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